Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.17    
    

STOCK PURCHASE AND SALE AGREEMENT  

        This Stock Purchase and Sale Agreement (as it may from time to time be amended, this "Agreement"), dated as of
October 25, 2007, is made and entered into by and among the Sellers identified on Schedule B hereto (each, a  "Seller" and
collectively, the  "Sellers") and John Merchant (the  "Buyer"). Certain capitalized terms are defined on Schedule A to this Agreement. 

RECITALS:  

        WHEREAS, the Sellers own an aggregate of 6,085,416 shares (the  "Shares") of the common stock, par value $0.0001 per share, of Prospect Acquisition Corp., a Delaware
corporation (the "Issuer"); and 

        WHEREAS, on the terms and subject to the conditions set forth in this Agreement, the Sellers wish to sell certain of the Shares in the
respective amounts set forth opposite each Seller's name on Schedule B to the Buyer and the Buyer wishes to purchase the Shares from the Sellers, in the respective amounts set forth on
Schedule B hereto. 

AGREEMENT:  

        NOW, THEREFORE, in consideration of the premises, representations, warranties and the mutual covenants contained
in this Agreement, and for other good and valuable consideration, the receipt, sufficiency and adequacy of which are hereby acknowledged, the parties hereto, intending legally to be bound, agree as
follows: 

ARTICLE I.

PURCHASE OF SHARES  

        Section 1.1    Sale of Shares.    Subject to the terms and conditions hereof and in reliance upon the
representations and warranties of the parties contained herein, at the Closing, each Seller shall sell, assign, transfer and deliver the Shares it is selling hereunder to the Buyer free and clear of
all liens, other than such restrictions as may be imposed pursuant to state or federal securities laws, in consideration of the payment of the Purchase Price noted herein. 

        Section 1.2    Purchase Price.    Subject to the terms and conditions hereof and in reliance upon the
representations and warranties of the parties contained herein, at the Closing, the Buyer shall pay to each Seller, by wire transfer or check payable, in immediately available funds, to the relevant
Seller, in the respective amounts set forth on Schedule B (the "Purchase Price"), in
consideration of the sale, assignment, transfer and delivery of the Shares by the Sellers under this Agreement. 

        Section 1.3    Closing.    The closing of the purchase and sale of the Shares (the  "Closing") shall be held on October 25, 2007 (the  "Closing Date") at the offices of Bingham McCutchen LLP,
 399 Park Avenue, New York,
New York 10022, or such other place as may be agreed upon by the parties hereto. 

        Section 1.4    Closing Deliveries.    At the Closing, each party shall execute and deliver this Agreement and
such other appropriate and customary documents as the other parties reasonably may request for the purpose of consummating the transactions contemplated by this Agreement. All actions taken at the
Closing shall be deemed to have been taken simultaneously. 

        (a)   Buyer Deliveries.    Without limiting the generality of the foregoing, at the Closing, the Buyer shall deliver
to each Seller, the relevant Purchase Price for the Shares being sold by the respective Seller to the Buyer. 

        (b)   Seller Deliveries.    Without limiting the generality of the foregoing, at the Closing, or within a reasonable
time after the Closing Date but in no event later than five days after Closing Date, each Seller shall deliver to the Buyer the certificate or certificates representing the Shares purchased by the 

 

Buyer,
which certificates shall be properly endorsed for transfer or accompanied by duly executed stock powers. 

        Section 1.5    Further Assurances.    The parties hereto shall execute and deliver such additional documents
and take such additional actions as any party reasonably may deem to be practical and necessary in order to consummate the transactions contemplated by this Agreement. 

ARTICLE II.

REPRESENTATIONS AND WARRANTIES OF THE BUYER  

        Section 2.1    Power and Authority; Enforceability.    The Buyer hereby represents to each Seller that,
(i) this Agreement constitutes its legal, valid, and binding obligation, enforceable against it in accordance with its terms, (ii) it has full power and authority to execute and deliver
this Agreement and to perform its obligations hereunder, (iii) it has taken all actions necessary to authorize the execution and delivery of this Agreement, the performance of its obligations
hereunder and the consummation of the transactions contemplated hereby, and (iv) this Agreement has been duly authorized, executed and delivered by, and is enforceable against, it, subject to
bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other laws of general applicability relating to or affecting creditors' rights and to general equitable principles
(whether considered in a proceeding in equity or law). 

        Section 2.2    No Violation; Necessary Approvals.    The Buyer hereby represents to each Seller, that neither
its execution and delivery of this Agreement, nor its consummation or performance of any of transactions contemplated hereby, will: (a) with or without notice or lapse of time, constitute,
create or result in a breach or violation of, default under, loss of benefit or right under or acceleration of performance of any obligation required under any (i) law (statutory, common or
otherwise), constitution, ordinance, rule, regulation, executive order or other similar authority
("Law") enacted, adopted, promulgated or applied by any legislature, agency, bureau, branch, department,
division, commission, court, tribunal or other similar recognized organization or body of any federal, state, county, municipal, local or foreign government or other similar recognized organization or
body exercising similar powers or authority (a "Governmental Body"), (ii) order, ruling,
decision, award, judgment, injunction or other similar determination or finding by, before or under the supervision of any Governmental Body or arbitrator (an  "Order"), (iii) contract, agreement, arrangement, commitment, instrument, document or similar
understanding (whether written or oral), including a lease, sublease and rights thereunder ("Contract")
or permit, license, certificate, waiver, notice and similar authorization ("Permit") to which, in the
case of (i), (ii) or (iii), it is a party or by which it is bound or any of its assets are subject, or (iv) any provision of the organizational documents of any Buyer, if applicable, as
in effect on the Closing Date; (b) require any Consent under any Contract or
organizational document, if applicable, to which it is a party or by which it is bound or any of its assets are subject; or (c) require any Permit under any Law or Order other than
(i) required filings, if any, with the Securities and Exchange Commission ("SEC") and
(ii) notifications or other filings with state or federal regulatory agencies after the Closing that are necessary or convenient and do not require approval of the agency as a condition to the
validity of the transactions contemplated hereunder. 

        Section 2.3    Investment Representations.    The Buyer hereby represents to each Seller, the following: 

        (a)   It
hereby acknowledges that an investment in the Shares involves certain significant risks. It acknowledges that there is a substantial risk that it will lose all or a
portion of its investment and should be financially capable of bearing the risk of such investment for an indefinite period of time. It has no need for liquidity in its investment in the Shares for
the foreseeable future and is able to bear the risk of that investment for an indefinite period. It understands that there presently is no public market for the Shares and none is anticipated to
develop in the foreseeable future. It's present 

2

 

financial
condition is such that it is under no present or contemplated future need to dispose of any portion of the Shares subscribed for hereby to satisfy any existing or contemplated undertaking,
need or indebtedness. It's overall commitment to investments which are not readily marketable is not disproportionate to its net worth and the investment in the Shares will not cause such overall
commitment to become excessive. 

        (b)   It
acknowledges that the Shares have not been registered under the Securities Act, or any state securities act, and are being sold on the basis of exemptions from
registration under the Securities Act and applicable state securities acts, except those state securities acts that require registration of the Shares thereunder. Reliance on such exemptions, where
applicable, is predicated in part on the accuracy of its' representations and warranties set forth herein. It acknowledges and hereby agrees that the Shares will not be transferable under any
circumstances unless it either registers the Shares in accordance with federal and state securities laws or finds and complies with an exemption under such laws. Accordingly, it hereby acknowledges
that there can be no assurance that it will be able to liquidate its investment in the Shares. It understands that the Issuer is under no obligation to register the Shares under the Act or to comply
with any applicable exemption under the Securities Act on behalf of the Buyer with respect to any resale of the Shares and that it will not be able to avail itself of the provisions of Rule 144
promulgated under the Securities Act with respect to the resale of the Shares until the Shares have been beneficially owned by it for a period of at least one (1) year from date of purchase. It
further understands that any certificates evidencing the Shares bear a legend referring to the foregoing transfer restrictions. 

        (c)   In
evaluating the merits and risks of an investment in the Shares, it has had the opportunity to seek the advice of its legal and financial advisors, has availed itself
of that right to the extent deemed appropriate, and has not relied on the advice of any Seller or Seller's legal and financial counsel. 

        (d)   The
Shares are being acquired solely for it's own account, for investment purposes only, and are not being purchased with a view to or for the resale, distribution,
subdivision or fractionalization thereof; and it has no present plans to enter into any contract, undertaking, agreement or arrangement for such resale, distribution, subdivision or fractionalization.
It is not taking and will not take or cause to be taken any action that would cause it to be deemed an "underwriter" within the meaning of Section 2(11) of the Securities Act. 

        (e)   There
are substantial risk factors pertaining to an investment in the Shares. It acknowledges that the Issuer is an entity with limited operating history and financial
resources; and it is fully able to bear the economic risks of such investment for an indefinite period, and can afford a complete loss thereof. 

        (f)    It
has been given the opportunity to (i) ask questions of and receive answers from the Sellers and the Issuer and their designated representatives concerning the
terms and conditions of the Shares, and the business and financial condition of the Issuer and (ii) obtain any additional information that the Sellers possess or can acquire without
unreasonable effort or expense that is necessary to assist it in evaluating the advisability of the purchase of the Shares and an investment in the Issuer. It further represents and warrants that,
prior to signing this Agreement, it has asked such questions, received such answers and obtained such information as it has deemed necessary or advisable to evaluate the merits and risks of the
purchase of the Shares and an investment in the Issuer. It is not relying on any oral representation made by any person as to the Issuer or its operations, financial condition or prospects. 

        (g)   It
understands that no federal, state or other governmental authority has made any recommendation, findings or determination relating to the merits of an investment in
the Shares. 

        Section 2.4    Agreement to Sell Back Securities.    The Buyer hereby agrees to permit
the Issuer to repurchase from the Buyer, in such proportion as the Buyer holds of the total outstanding Shares of 

3

 

the
Issuer immediately prior to the Issuer's initial public offering of its securities (the "Designated
Time"), at a purchase price equal to $0.0001 per share, a number of Shares necessary to ensure that the aggregate amount of Shares held by the Buyer,
any transferees pursuant to Section 3.4(i) and all other holders of the Issuer's outstanding Shares at the Designated Time, does not exceed 20% of the issued and outstanding common stock
of the Issuer after the consummation of the Issuer's initial public offering of its securities. 

ARTICLE III.

REPRESENTATIONS AND WARRANTIES OF THE SELLERS  

        Section 3.1    Power and Authority; Enforceability.    Each Seller hereby represents to the Buyer, as to
itself, that this Agreement constitutes its legal, valid, and binding obligation, enforceable against it in accordance with its terms. It has full power and capacity to execute and deliver this
Agreement and to perform its obligations hereunder. This Agreement has been duly executed, and delivered by, and is enforceable against, it. 

        Section 3.2    No Violation; Necessary Approvals.    Each Seller hereby represents to the Buyer, as to itself,
that (i) neither its execution and delivery of this Agreement, nor its consummation or performance of any of transactions contemplated hereby, will: (a) with or without notice or lapse
of time, constitute, create or result in a breach or violation of, default under, loss of benefit or right under or acceleration of performance of any obligation required under any Law, Order,
Contract or Permit to which it is a party or by which it is bound or any of its assets are subject, (b) result in the imposition of any lien, claim or encumbrance upon any assets owned by it;
(c) require any Consent under any Contract or organizational document, if applicable, to which it is a party or by which it is bound; or (d) require any Permit under any Law or Order
other than (i) required filings, if any, with the SEC and (ii) notifications or other filings with state or federal regulatory agencies after the Closing that are necessary or convenient
and do not require approval of the agency as a condition to the validity of the transactions contemplated hereunder; or (e) trigger any rights of first refusal, preferential purchase or similar
rights with respect to any of the Shares. 

        Section 3.3    Capitalization.    Prior to the sale of the Shares to the Buyer pursuant to this Agreement, each
Seller hereby represents and warrants to the Buyer that they owned in the aggregate, the number of shares of common stock of the Issuer identified on Schedule B. 

        Section 3.4    Title to Securities.    Each Seller hereby represents to the Buyer, as to itself, that all of
the Shares being sold by the Seller hereunder have been duly and validly authorized and issued and are fully paid and non-assessable. Upon the sale and purchase of the Shares pursuant to the terms
hereof, the Buyer will have or receive good title to the Shares being sold by the Sellers hereunder, free and clear of all liens, claims and encumbrances of any kind, other than (i) transfer
restrictions under federal and state securities laws, and (ii) liens, claims or encumbrances imposed due to the actions of the Buyer. 

4

   ARTICLE IV.

MISCELLANEOUS  

        Section 4.1    Entire Agreement.    This Agreement, together with the certificates, documents, instruments and
writings that are delivered pursuant hereto, constitutes the entire agreement and understanding of the parties hereto in respect of its subject matter and supersedes all prior understandings,
agreements, or representations by or among the parties hereto, written or oral, to the extent they relate in any way to the subject matter hereof or the transactions contemplated hereby. 

        Section 4.2    Successors.    All of the terms, agreements, covenants, representations, warranties, and
conditions of this Agreement are binding upon, and inure to the benefit of and are enforceable by, the parties hereto and their respective successors. 

        Section 4.3    Assignments.    Except as otherwise provided herein, no party hereto may assign either this
Agreement or any of its rights, interests, or obligations hereunder without the prior written approval of the other party, other than an assignment by the Buyer to an affiliate thereof. Any purported
assignment in violation of this Section 4.3 shall be void and ineffectual and shall not operate to transfer or assign any interest or title to the purported assignee. 

        Section 4.4    Notices.    All notices, requests, demands, claims and other communications hereunder will be in
writing. Any notice, request, demand, claim or other communication hereunder will be deemed duly given if (and then three business days after) it is sent by registered or certified mail, return
receipt requested, postage prepaid, and addressed to the intended recipient as set forth below: 

	If to the Buyer:	 	John Merchant

48 Evergreen Circle

Canton, MA 02021
	

If to the Sellers:	
 	

To the address

set forth below such

Seller's name on the

Schedule B hereto.
	

Copy to (which will not constitute notice):	
 	

Bingham McCutchen LLP

399 Park Avenue

New York, New York 10022

Attn: Floyd I. Wittlin, Esq.

Phone: (212) 705-7000

Fax: (212) 752-5378

        Any
party hereto may send any notice, request, demand, claim, or other communication hereunder to the intended recipient at the address set forth above using any other means (including
personal delivery, expedited courier, messenger service, telecopy, telex, ordinary mail, or electronic mail), but no such notice, request, demand, claim, or other communication will be deemed to have
been duly given unless and until it actually is received by the intended recipient. Any party hereto may change the address to which notices, requests, demands, claims, and other communications
hereunder are to be delivered by giving the other parties hereto notice in the manner herein set forth. 

        Section 4.5    Specific Performance.    Each party hereto acknowledges and agrees that the other parties would
be damaged irreparably if any provision of this Agreement is not performed in accordance with its specific terms or is otherwise breached. Accordingly, each party agrees that the other parties will be
entitled to an injunction or injunctions to prevent breaches of the provisions of this Agreement and to enforce specifically this Agreement and its terms and provisions in any action instituted in any
court of the United States or any state thereof having jurisdiction over the parties 

5

 

hereto
and the matter, in addition to any other remedy to which they may be entitled, at Law or in equity. 

        Section 4.6    Waiver of Jury Trial.    THE PARTIES HERETO EACH HEREBY AGREE TO WAIVE THEIR RESPECTIVE RIGHTS
TO JURY TRIAL OF ANY DISPUTE BASED UPON OR ARISING OUT OF THIS AGREEMENT OR ANY OTHER AGREEMENTS RELATING HERETO OR ANY DEALINGS AMONG THEM RELATING TO THE TRANSACTIONS. THE SCOPE OF THIS WAIVER IS
INTENDED TO BE ALL ENCOMPASSING OF ANY AND ALL ACTIONS THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THE TRANSACTIONS, INCLUDING, CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY
CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THE PARTIES HERETO EACH ACKNOWLEDGE THAT THIS WAIVER IS A MATERIAL INDUCEMENT TO ENTER INTO A BUSINESS RELATIONSHIP AND THAT THEY WILL CONTINUE
TO RELY ON THE WAIVER IN THEIR RELATED FUTURE DEALINGS. EACH PARTY HERETO FURTHER REPRESENTS AND WARRANTS THAT IT HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT EACH KNOWINGLY AND
VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. NOTWITHSTANDING ANYTHING TO THE CONTRARY HEREIN, THIS WAIVER IS IRREVOCABLE, MEANING THAT IT MAY NOT BE MODIFIED
ORALLY OR IN WRITING, AND THE WAIVER WILL APPLY TO ANY AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO THIS AGREEMENT OR TO ANY OTHER DOCUMENTS OR AGREEMENTS RELATING HERETO. IN THE EVENT OF AN
ACTION, THIS AGREEMENT MAY BE FILED AS A WRITTEN CONSENT TO TRIAL BY A COURT. 

        Section 4.7    Counterparts.    This Agreement may be executed in two or more counterparts, each of which will
be deemed an original but all of which together will constitute one and the same instrument. 

        Section 4.8    Headings.    The article and section headings contained in this Agreement are inserted for
convenience only and will not affect in any way the meaning or interpretation of this Agreement. 

        Section 4.9    Governing Law.    This Agreement, the entire relationship of the parties hereto, and any
litigation between the parties (whether grounded in contract, tort, statute, law or equity) shall be governed by, construed in accordance with, and interpreted pursuant to the laws of the State of New
York, without giving effect to its choice of laws principles. 

        Section 4.10    Amendments.    This Agreement may not be amended, modified or waived as to any particular
provision, except by a written instrument executed by all parties hereto. 

        Section 4.11    Severability.    The provisions of this Agreement will be deemed severable and the invalidity
or unenforceability of any provision will not affect the validity or enforceability of the other provisions hereof; provided that if any provision of this Agreement, as applied to any party hereto or
to any circumstance, is adjudged by a Governmental Body, arbitrator, or mediator not to be enforceable in accordance with its terms, the parties hereto agree that the Governmental Body, arbitrator, or
mediator making such determination will have the power to modify the provision in a manner consistent with its objectives such that it is enforceable, and/or to delete specific words or phrases, and
in its reduced form, such provision will then be enforceable and will be enforced. 

        Section 4.12    Expenses.    Except as otherwise expressly provided in this Agreement, each party hereto will
bear its own costs and expenses incurred in connection with the preparation, execution and performance of this Agreement and the consummation of the transactions contemplated hereby, including all
fees and expenses of agents, representatives, financial advisors, legal counsel and accountants, provided that upon the consummation of the initial public offering of the Issuer, all such accrued fees
and expenses of legal counsel of the Buyer shall be paid by the Issuer. 

6

 

        Section 4.13    Construction.    The parties hereto have participated jointly in the negotiation and drafting
of this Agreement. If an ambiguity or question of intent or interpretation arises, this Agreement will be construed as if drafted jointly by the parties hereto and no presumption or burden of proof
will arise favoring or disfavoring any party hereto because of the authorship of any provision of this Agreement. Any reference to any federal, state, local, or foreign Law will be deemed also to
refer to Law as amended and all rules and regulations promulgated thereunder, unless the context requires otherwise. The words "include,"
"includes," and "including" will be deemed to be followed by "without
limitation." Pronouns in masculine, feminine, and neuter genders will be construed to include any other gender, and words in the singular form will be construed to include the
plural and vice versa, unless the context otherwise requires. The words "this Agreement," "herein,"
"hereof," "hereby," "hereunder," and words of similar
import refer to this Agreement as a whole and not to any particular subdivision unless expressly so limited. The parties hereto intend that each representation, warranty, and covenant contained herein
will have independent significance. If any party hereto has breached any representation, warranty, or covenant contained herein in any respect, the fact that there exists another representation,
warranty or covenant relating to the same subject matter (regardless of the relative levels of specificity) which such party hereto has not breached will not detract from or mitigate the fact that
such party hereto is in breach of the first representation, warranty, or covenant. 

        Section 4.14    Waiver.    No waiver by any party hereto of any default, misrepresentation, or breach of
warranty or covenant hereunder, whether intentional or not, may be deemed to extend to any prior or subsequent default, misrepresentation, or breach of warranty or covenant hereunder or affect in any
way any rights arising because of any prior or subsequent occurrence. 

        Section 4.15    Remedies.    The parties hereto shall have all remedies for breach of this Agreement available
to them as provided by law or equity. 

        Section 4.16    Publicity.    None of the parties hereto, nor their respective representatives, agents,
affiliates, subsidiaries, directors, advisors, controlling persons, employees or members shall issue or cause the publication of any press release, advertisement or other public communication relating
to this Agreement or any of the other documents contemplated hereunder, without the prior written consent of the other party, except where the disclosure of information is required by law, rule,
regulation, regulatory inquiry or other judicial process. 

        Section 4.17    Third Party Beneficiary.    Each of the parties hereto hereby agrees and acknowledges that the
Issuer shall be a third party beneficiary of this Agreement with respect to Section 2.4 and this Article IV as if the Issuer shall have been a party to this Agreement. 

7

        IN WITNESS WHEREOF, the undersigned have executed this Stock Purchase and Sale Agreement to be effective as of the date first set forth above. 

	 	 	JOHN MERCHANT
	

    	
 	

By:	

/s/  JOHN MERCHANT      

	

 	
 	
FLAT RIDGE INVESTMENTS LLC
	

    	
 	

By:	

/s/  DAVID A. MINELLA      

	 	 	Name:	David A. Minella
	 	 	Title:	Managing Member
	

    	
 	
LLM STRUCTURED EQUITY FUND L.P.
	

    	
 	

By:	

/s/  PATRICK J. LANDERS      

	 	 	Name:	Patrick J. Landers
	 	 	Title:	 
	

    	
 	
LLM INVESTORS L.P.
	

    	
 	

By:	

/s/  PATRICK J. LANDERS      

	 	 	Name:	Patrick J. Landers
	 	 	Title:	 
	

 	
 	
CAPITAL MANAGEMENT SYSTEMS, INC.
	

    	
 	

By:	

/s/  INGRID R. WELCH      

	 	 	Name:	Ingrid R. Welch
	 	 	Title:	Vice President

[Signature Page to Stock Purchase Agreement] 

 
 

SCHEDULE A
  DEFINITIONS    
    

        As used in the Stock Purchase and Sale Agreement dated as of October 25, 2007, by and among the Sellers identified on Schedule B and John Merchant
(the "Agreement"), the following terms shall have for all purposes the following meanings:: 

        "Buyer" shall have the meaning set forth in the preamble to the Agreement. 

        "Closing" shall have the meaning set forth in Section 1.3 of the Agreement. 

        "Closing Date" shall have the meaning set forth in Section 1.3 of the Agreement. 

        "Consent" means any consent, approval, notification, waiver, or other similar action that is necessary or convenient. 

        "Contract" shall have the meaning set forth in Section 2.3 of the Agreement. 

        "Designated Time" shall have the meaning set forth in Section 2.5 of the Agreement. 

        "Governmental Body" shall have the meaning set forth in Section 2.3 of the Agreement. 

        "Issuer" shall have the meaning set forth in the recitals to the Agreement. 

        "Law" shall have the meaning set forth in Section 2.3 of the Agreement. 

        "Lien" shall mean a mortgage, deed of trust, pledge, hypothecation, assignment, encumbrance, charge, restriction, lien (statutory or
otherwise, including, without limitation, any lien for taxes), security interest, preference, participation interest, priority or security agreement or preferential arrangement of
any kind or nature whatsoever, including, without limitation, any conditional sale or other title retention agreement, any financing lease having substantially the same economic effect as any of the
foregoing and the filing of any document under the law of any applicable jurisdiction to evidence any of the foregoing, other than (i) statutory, mechanics' or other Liens incurred in the
ordinary course of business or (ii) Liens for taxes incurred but not yet due. 

        "Order" shall have the meaning set forth in Section 2.3 of the Agreement. 

        "Permit" shall have the meaning set forth in Section 2.3 of the Agreement. 

        "Purchase Price" shall have the meaning set forth in Section 1.2 of the Agreement. 

        "SEC" shall have the meaning set forth in Section 2.3 of the Agreement. 

        "Securities Act" shall mean the Securities Act of 1933, as amended, or any successor federal statute, and the applicable rules and
regulations promulgated and in effect from time to time thereunder. 

        "Seller" and "Sellers" shall have the meaning set forth in the preamble to the Agreement. 

        "Shares" shall have the meaning set forth in the recitals to the Agreement. 

SCHEDULE B  

SHARES 

	Seller
 
	 	Shares

Currently

Owned
	 	Shares Sold to

Flat Ridge
	 	Sales Price

Shares Sold to

Flat Ridge

	Flat Ridge Investments LLC

814 Hollow Tree Ridge Road

Darien, CT 02820	 	3,863,281	 	100,765	 	$	350.49
	

LLM Structured Equity Fund L.P.

265 Franklin St., 20th Floor

Boston, MA 02110	
 	

1,742,155	
 	

45,440	
 	
$	

158.05
	

LLM Investors L.P.

265 Franklin St., 20th Floor

Boston, MA 02110	
 	

35,553	
 	

927	
 	
$	

3.22
	

Capital Management Systems, Inc.

308 E. Lancaster Avenue

Suite 300

Wynnewood, PA 19096	
 	

444,427	
 	

11,592	
 	
$	

40.32
	

 	
 	

 	
 	

	
 	

	 	
Total	
 	

 	
 	

158,724	
 	
$	

552.08
	

 	
 	

 	
 	

	
 	

QuickLinks

Exhibit 10.17

SCHEDULE A DEFINITIONSExhibit
10.34

 

SUPPLY AGREEMENT

 

SUPPLY AGREEMENT (“Agreement”) dated as of
September 23, 2003, (“Effective Date”) between RELIANT PHARMACEUTICALS, LLC, a
Delaware limited liability company (“Reliant”), and AUSTIN SHASUN, LLC, an
Illinois limited liability company (“ASL”).

 

WHEREAS, ASL and Reliant desire to enter into
this Agreement which will set forth the terms and conditions under which ASL
shall supply to Reliant bulk quantities of the Active Ingredient (as
hereinafter defined) for use in the manufacture of the Products (as hereinafter
defined);

 

NOW THEREFORE, in consideration of the mutual
covenants and consideration set forth herein, the parties hereto agree as
follows:

 

SECTION 1

 

DEFINITIONS

 

SECTION 1.1.        As used herein, the
following defined terms shall have the definitions set forth below:

 

(a)           “Act” shall mean the Federal Food Drug and
Cosmetic Act (21 U.S.C. §301 et seq) as amended from time to time and the
regulations promulgated thereunder and corresponding legislation in any other
country where the Active Ingredient is manufactured.

 

(b)           “Active Ingredient” or “API” shall mean
isradipine.

 

(c)           “Adverse Events” shall mean any serious or
unexpected side effect, injury, toxicity, or sensitivity reaction, or any
adverse drug reaction reports and the severity thereof associated with the
Product where the term “serious” as used in this Section refers to an
experience which results in death, permanent or substantial disability, a
vegetative state, inpatient hospitalization or prolongation of hospitalization,
a congenital anomaly, cancer, an overdose, or is life threatening. The term “unexpected”
as used in this definition means an adverse drug experience that is not listed
in the then current labeling for the Product and includes an event that may be
symptomatically or pathophysiologically related to an event listed in the
labeling, but differs from the event because of greater severity or
specificity.

 

(d)           “Affiliate” shall mean all corporations or
business entities which, directly or indirectly, are controlled by, control or
are under common control by any of ASL or Reliant, as the case may be. For this
purpose, “control” shall mean the possession, direct or indirect, of the power
to direct or cause the direction of the management and policies of a person or
entity, whether through the ownership of at least fifty percent (50%) of the
voting shares or interest of such person or entity, by contract or otherwise.

 

(e)           “Agreement Year” shall mean each twelve (12)
month period of the term of this Agreement beginning on the first day of the
calendar year except for the “First Agreement Year”

 

 

which shall
mean the period commencing on the Effective Date and ending on December 31,
2003.

 

(f).           “Annual Payment Amount” shall have the
meaning set forth in Section 2.7(c).

 

(g)           “Annualized Purchase Amount” shall have the
meaning set forth in Section 2.7(d).

 

(h)           A “Bankruptcy Event” shall have occurred
when the person or entity in question becomes insolvent, or voluntary or
involuntary proceedings by or against such person or entity are instituted in
bankruptcy or under any insolvency law, or a receiver or custodian is appointed
for such person or entity, or proceedings are instituted by or against such
person or entity for corporate reorganization or the dissolution of such person
or entity, which proceedings, if involuntary, shall not have been dismissed
within one hundred and twenty (120) days after the date of filing, or such
person or entity makes an assignment for the benefit of its creditors, or
substantially all of the assets of such person or entity are seized or attached
and not released within one hundred and twenty (120) days thereafter.

 

(i)            “Claims” shall have the meaning ascribed in
Section 2.9.

 

(j)            “Designated Facility” shall mean a location
in the Territory set forth by Reliant in the applicable purchase order.

 

(k)           “Drug Master File” or “DMF’ means a
submission to the FDA by ASL that may be used to provide confidential detailed
information about facilities, processes or articles used in the manufacturing,
processing, packaging and storing of the Active Ingredient.

 

(l)            “DynaCirc” shall mean isradipine capsules
(2.5 mg and 5 mg) marketed by Reliant pursuant to the NDA under the brand name
DynaCirc®.

 

(m)          “DynaCirc CR” shall mean controlled release
isradipine capsules (5 mg and 10 mg) marketed by Reliant pursuant to the NDA
under the brand name DynaCirc CR®.

 

(n)           “Effective Date” shall mean the date first
shown above.

 

(o)           “FDA” shall mean the United States Food and
Drug Administration or any successor entity performing similar functions.

 

(p)           “First Commercial Sale” shall mean the date
on which Reliant (or any Affiliate of Reliant) sells the first Product to an
unaffiliated third party utilizing API supplied by ASL pursuant to this
Agreement.

 

(q)           “GMP” shall mean current Good Manufacturing
Practice as defined in 21 CFR §210.211 as may be amended from time to time.

 

(r)            “Improvements” shall mean any improved
Products, line extensions, modified Products or similar items which contain the
Active Ingredient and which Reliant obtains rights to, develops or sells during
the course of this Agreement.

 

2

 

(s)           “Initial Forecast” shall have the meaning
ascribed in Section 2.8(a).

 

(t)            “Initial Products” shall mean DynaCirc and
DynaCirc CR manufactured using bulk amounts of the Active Ingredient supplied
by ASL.

 

(u)           “Losses” shall have the meaning ascribed in
Section 3.2.

 

(v)           “NDA” shall mean the New Drug Applications,
19-596 (DynaCirc) and 20-336 (DynaCirc CR) as amended and supplemented, to
market the Products and any materials, documents or information referred to or
relied upon therein.

 

(w)          “Process Description” shall mean, with
respect to the Active Ingredient, good manufacturing procedures (including, but
not limited to, FDA quality system requirements and procedures), as well as
such other know-how, technical specifications, instructions, processes and
other intellectual property and information Reliant shall possess and as shall
be necessary in order to allow ASL to manufacture and/or have manufactured the
Active Ingredient.

 

(x)            “Products” shall mean the Initial Products,
and any Improvements thereto including all formulations containing Active
Ingredient in all strengths, dosage forms and presentations.

 

(y)           “Product Quality Complaint” shall mean any
complaint that questions the purity, identity, potency or quality of the Active
Ingredient.

 

(z)            “Purchase Price” shall have the meaning
ascribed in Section 2.7.

 

(z2)          “Quality Agreement” refers to the form of Quality
Agreement attached as Exhibit C.

 

(z3)          “Quarterly Forecast” shall have meaning
ascribed in Section 2.8(a).

 

(aa)         “Receipt Date” shall mean the earliest date on
which a party or its Affiliate first becomes aware of the Adverse Event.

 

(bb)         “Regulatory Approval” shall mean, with respect
to the Products, the FDA’s regulatory approval of the amendment to the NDA
authorizing the use of Active Ingredient manufactured by ASL in the Initial
Products.

 

(cc)         “Regulatory Filings” shall mean all
applications, filings, materials, studies, data and documents of any nature
whatsoever (including any supporting information related thereto) filed with,
or prepared in connection with, the Regulatory Approval.

 

(dd)         “Specifications” shall have the meaning
ascribed in 2.2.

 

(ee)         “Term” shall have the meaning ascribed in 3.5.

 

(ff)           “Territory” shall mean the United States,
its territories and possessions including Puerto Rico.

 

3

 

SECTION 2

 

SUPPLY AGREEMENT

 

SECTION 2.1.        Supply of the Active
Ingredient.

 

(a)           During the term of this Agreement, and
subject to the other terms and conditions hereof, ASL shall supply and sell to
Reliant and Reliant shall purchase from ASL all of Reliant’s requirements for
the Active Ingredient pursuant to the terms of this Agreement. Notwithstanding
the preceding sentence, Reliant’s obligation to purchase all of its
requirements of API from ASL is contingent upon ASL’s ability to manufacture
all Reliant’s requirements, receipt by Reliant of Regulatory Approval and is
further subject to Reliant’s obligations to purchase minimum quantities of
Active Ingredient from Novartis pursuant to that certain Supply Agreement by
and between Reliant and Novartis dated January 10, 2003.

 

(b)           During the term of this Agreement and
provided that Reliant complies with its purchase obligations set forth herein,
ASL shall not supply or sell the Active Ingredient to any other purchaser in
the Territory or outside the Territory for sale of any product containing the
Active Ingredient inside the Territory without the prior written consent of
Reliant (provided, however, that nothing herein shall affect ASL’s ability to
manufacture products which are not the Active Ingredient).

 

(c)           ASL shall supply Reliant with Active
Ingredient meeting the Specifications. All Active Ingredient supplied by ASL to
Reliant hereunder shall be consistent with the DMF and NDA and produced in a
facility and in a manner compliant with GMP and all other applicable laws, and
shall not be adulterated or misbranded within the meaning of the Act and will
have expiration dating of at least twenty four (24) months from the date of
manufacture. Each shipment of Active Ingredient from ASL to Reliant shall be
sampled and analyzed by ASL to determine if the shipment of Active Ingredient
meets the Specifications. ASL shall deliver with each shipment of the Active
Ingredient a certificate of analysis stating that the Active Ingredient meets
the Specifications. ASL shall not relocate or otherwise transfer the site of manufacture
of API without the express prior written approval of Reliant in the absence of
a force majeure event or unremedied audit deficiencies under Section 2.3 below.
Upon delivery to the Designated Facility, title to the Active Ingredient so
delivered will be free and clear of any security interest or other encumbrance
created by ASL.

 

SECTION 2.2.        Specifications.

 

(a)           The specifications (“Specifications”) for
the Active Ingredient are set forth on Exhibit A.

 

(b)           All Active Ingredient supplied to Reliant
hereunder shall be supplied in bulk form in drums and on pallets or as
otherwise agreed by the parties. The packaging requirements shall be specified
in the Specifications.

 

(c)           No changes to the Specifications or to the
Active Ingredient shall be made by ASL without the prior written approval of
Reliant unless expressly required either under GMP or the Act. In addition, any
changes to the Active Ingredient, the Specifications or the

 

4

 

manufacturing
process which may require the submission of any amendment, filing or other
documentation with the FDA and could potentially impact the NDA or other
Regulatory Filings shall be identified, reviewed and require the written
approval of Reliant. To the extent reasonably practicable, Reliant shall
provide a response to any such proposed changes within twenty (20) business
days after receipt

 

SECTION 2.3.        Audit of Manufacturing
Facility.

 

(a)           Reliant or its representatives shall have
the right, upon not less than five (5) business days advance notice and during
regular business hours, to inspect and audit any facilities being used by ASL
and any of its Affiliates, subsidiaries, joint ventures or other entities for
the manufacture, production or supply or storage of the Active Ingredient (“Supply
Facilities”) including all documentation related thereto to assure compliance
by ASL or its suppliers with the terms of this Agreement, applicable US laws,
rules and regulations including GMP and the prevailing FDA quality system
requirements. Such inspection and audit shall be limited to those portions of
such Supply Facilities as are involved in the production of the Active
Ingredient, and shall be, conducted in a manner so as to minimize disruption of
ASL’s and the inspected facilities’ business operations. ASL shall ensure
Reliant has access to all such Supply Facilities (including, but not limited
to, any third party facilities) in accordance with the foregoing in order for
Reliant to conduct such audits; provided, however, that Reliant shall be
subject to such reasonable confidentiality obligations as may be required by
such third party in order to protect any proprietary information.

 

(b)           If any of such audits reveal that the Supply
Facilities do not satisfy the requirements of this Agreement or the Act, then
Reliant shall provide written notice of such fact, which notice shall contain
in reasonable detail (including reference to the applicable standard or
criteria which has not been met) the deficiencies found in the Supply
Facilities and, if practicable, those steps which should be undertaken in order
to remedy such deficiencies. ASL shall within thirty (30) days remedy any
deficiencies from any such audit which have been provided to ASL in writing. In
the event that ASL does not remedy, or is incapable of remedying, any of such
deficiencies within such thirty (30) day period, ASL shall have the option to
locate and qualify alternate GMP qualified Supply Facilities from which to
perform its supply obligations under this Agreement. Should ALSA not locate and
qualify such alternate GMP qualified Supply Facilities within 90 days of
receiving Reliant’s notice, then Reliant shall be entitled to terminate this
Agreement upon written notice to ASL, in which event ASL shall provide Reliant
at ASL’s cost such assistance and any other information (including the Process
Descriptions) as shall be necessary in order for Reliant to manufacture or have
manufactured the Active Ingredient at another facility.

 

(c)           ASL acknowledges that the provisions of this
Section 2.3 granting Reliant certain audit rights shall in no way relieve ASL
of any of its obligations under this Agreement, nor shall such provisions
require Reliant to conduct any such audits.

 

SECTION 2.4.        Notice of Audit.

 

(a)           Notice. ASL shall give Reliant
immediate notice of any impending FDA or other governmental audit of ASL as it
relates to the manufacture, production or testing storage of

 

5

 

Active
Ingredient supplied to Reliant pursuant to this Agreement and shall provide
Reliant with any documentation provided to it relating to such audit. ASL shall
provide Reliant the opportunity for a 15-day, or a mutually-agreed timeline for
review, prior to submission, any documentation prepared in response to such
governmental audit and shall promptly provide Reliant with the results of such
audit following its conclusion.

 

(b)           Inspection Reports. ASL shall
promptly provide to Reliant copies of any FDA or other US governmental
inspection reports it receives from the FDA or other US governmental agency
with jurisdiction over the manufacturing facility with respect to the
manufacturing facilities which supply the Active Ingredient.

 

(c)           Regulatory Inspections. ASL shall
promptly notify Reliant of any FDA or other US regulatory inspections of the
facilities which supply the Active Ingredient.

 

SECTION 2.5.        Notice of Regulatory
Action.

 

ASL shall provide Reliant with immediate
notification of its receipt of any of the following related to the manufacture,
production or testing storage of the Active Ingredient; a copy of any list of
observations (Form FD483), Warning Letters, Information Letters, Regulatory
Letters or the like issued by the FDA as well as provide Reliant an opportunity
to review any written response prior to submission to the FDA. ASL shall
maintain sole responsibility for any matter pertaining to such inspections.

 

SECTION 2.6.        Recordkeeping.

 

ASL shall keep and maintain all production,
batch, control laboratory and other records in accordance with all applicable
FDA laws, roles and regulations including but not limited to GMP. Such records
shall be made available to Reliant or its representatives upon request.

 

SECTION 2.7.        Orders, Prices and
Terms.

 

(a)           Purchase Price. The purchase price (“Purchase
Price”) for the Active Ingredient purchased from ASL for a period of three (3)
years from the date of Regulatory Approval for either of the Initial Products
(the “Initial Pricing Period”) shall be as set forth on Exhibit B hereto. In
the event that Reliant fails to order at least 150 kgs of Active Ingredient
(the “Minimum”) in any year of the Initial Pricing Period (excluding the “First
Agreement Year”), and fails to cure such failure in the Quarterly Forecast for
the succeeding Agreement Year, ASL shall have the right to renegotiate the
Purchase Price. Price increases will be limited to ASL’s direct incremental
price increase for raw materials directly attributable to the lower than
expected volume purchases of raw materials by ASL as demonstrated from ASL’s
records. The Purchase Price for each purchase order shall be determined by the
relevant Tier on Exhibit B according to the aggregate number of kilograms of
API purchased to date within the relevant Agreement Year. The Purchase Price
set forth on Exhibit B may be renegotiated at any time and from time to time
after expiration of the Initial Period. Any change in the Purchase Price of

 

6

 

Active
Ingredient following expiration of the Initial Pricing Period provided,
however, that the Purchase Price for Active Ingredient shall not be increased
greater than the annual increase in any Agreement Year during the Term by
greater than the annual increase in the Producer Price Industry Data figure for
pharmaceutical preparations (PCU 2834) as published by the US Department of
Labor.

 

(b)           Effect of Specification Changes on
Purchase Price. Notwithstanding the foregoing, in the event that Reliant
requests a change to the Specifications, ASL shall notify Reliant within 30
days of ASL’s receipt of such request whether the requested change will result
in a material increase or decrease in the direct cost of manufacture of the
Active Ingredient and ASL’s estimate of the cost of implementing the change. If
Reliant then confirms to ASL that it wants to have the change implemented, then
Reliant shall reimburse ASL for the estimated costs of implementing the change
and pay such increased or decreased price, as the case may be, for API in an
amount that enables ASL to pass through its consequent direct cost increases or
decreases

 

(c)           Quarterly Reconciliation. Within
thirty-(30) days of the last day of each calendar quarter, a quarterly
reconciliation shall be calculated by multiplying the total number of kgs
purchased by Reliant in such quarter by the cost/kg in the relevant Tier in
Exhibit B, and subtracting such amounts invoiced Reliant during such quarter
(the difference is the “the Quarterly Payment”). If the Quarterly Payment
Amount is less than zero ($0.00), ASL shall credit Reliant that entire amount
by way of a volume rebate in Kgs in the next invoice to Reliant for purchases.

 

(d)           Annual Reconciliation: During each
Agreement Year, ASL shall invoice Reliant for purchases as set forth in Exhibit
B. Within 30-days of the last day of each Agreement Year, an annual
reconciliation will be calculated by multiplying the total number of kilograms
of API purchased for the relevant agreement year by the relevant price in
appropriate Tier in Exhibit B, and subtracting the total invoiced amount in
dollars for such Agreement Year (the difference is the “Annual Payment Amount”).
If the Annual Payment Amount is less than zero ($0.00), ASL shall credit
Reliant that entire amount by way of a volume rebate in Kgs (the “Volume Rebate”)
in the next invoice to Reliant for purchases.

 

(e)           Invoices and Payments. ASL will
invoice Reliant within thirty-(30) days after delivery and acceptance of each
shipment of Active Ingredient to Reliant or Designated Facility. Reliant shall
pay ASL for API accepted within thirty-(30) days of receipt of the relevant
invoice. All payments shall be made in U.S. dollars without deduction of any
kind such as for withholding taxes or claims of set-off other than in the case
of a bona fide dispute with respect to this Agreement. If Reliant has not paid
the invoice within such thirty (30) day period (other than amounts related to
amounts subject to bona fide dispute), Reliant shall pay interest on any unpaid
and undisputed amounts at the rate of 1 1⁄2% per month or the maximum rate
allowed by law whatever is lower until paid in full, and, if the dispute is
resolved in ASL’s favor, Reliant shall pay interest at such rate on the
disputed amount until paid in full.

 

 

7

 

SECTION 2.8.        Forecasts and Purchase
Orders.

 

(a)           Following Regulatory Approval of one of the
Initial Products during the term of this Agreement, Reliant shall provide to
ASL no later than the first day of the first month of each calendar quarter a
non-binding good faith estimate (“Quarterly Forecast”) by quarter of Reliant’s
requirements for the Active Ingredient for the calendar quarter and the
succeeding three (3) calendar quarters. Reliant will be obligated to purchase
75% of the quantities of API forecasted for the first two (2) succeeding
calendar quarters of each Quarterly Forecast. Within (30) days of Regulatory
Approval, Reliant shall provide an initial forecast (“Initial Forecast”) for
the four calendar quarters following Regulatory Approval.

 

(b)           Reliant shall place binding purchase orders
for Active Ingredient by written or electronic purchase order (or by any other
means agreed to by the parties) to ASL, which shall be placed at least ninety
(90) days prior to desired date of delivery.

 

(c)           ASL shall be obligated to supply Active
Ingredient as ordered by Reliant. To the extent purchase orders in any calendar
month exceed One Hundred Fifty percent (150%) of the Quarterly Forecast for the
relevant quarter, ASL shall use its best efforts to supply 125% of the quantity
ordered.

 

 (d)          ASL shall maintain
minimum inventory levels equal to the binding portion of the then current
Quarterly Forecast. The Active Ingredient shall be shipped C.I.F. Duty Unpaid
to a Designated Facility or other location agreed by the parties. Active
Ingredient shall be shipped upon completion of production in
temperature-controlled vehicles in accordance with the specifications including
light protecting containers and the Quality Agreement in order to maintain the
quality of the Active Ingredient. Carriers selected by ASL must be commercially
reputable, able to track shipments and fully insured with adequate coverage to
replace the value of the goods shipped. Title and risk of loss pass on delivery
to the Designated Facility.

 

(e)           All shipments of Active Ingredient shall be
accompanied by a packing slip and a certificate of analysis which describes the
Active Ingredient, states the purchase order number, confirms that the Active
Ingredient conforms in all ways with the Specifications, the Process
Description and was manufactured in accordance with GMP and all other
requirements of the Act. To the extent of any conflict or inconsistency between
this Agreement and any purchase order, purchase order release, confirmation,
acceptance or any similar document, the terms of this Agreement shall govern.

 

(f)            Reliant shall notify ASL of any
short-shipment claims within thirty (30) days of receipt of a shipment of
Active Ingredient.

 

(g)           ASL shall not be obligated to accept any
returns of Active Ingredient other than as a result of such Active Ingredient
failing to meet the Specifications in accordance with Section 2.9(a), was not
manufactured in accordance with GMP, or does not otherwise comply with the
manufacturing, storage and/or transportation requirements of the Act.

 

8

 

SECTION 2.9.        Product Claims.

 

(a)           After delivery of a shipment of any Active
Ingredient to Reliant, Reliant shall have sixty (60) days to examine the Active
Ingredient to determine if it conforms to the Specifications and, on the basis
of such examination, to accept or reject such shipment. Any claims for failure
to so conform (“Claims”) shall be made by Reliant in writing within such sixty
(60) day period to ASL, indicating the nonconforming characteristics of the
Active Ingredient.

 

(b)           If ASL agrees with such Claim, then as
promptly as possible after the submission of a Claim by Reliant, ASL shall, at
Reliant’s option, provide Reliant (i) with a credit against future billings equal
to the full amount paid by Reliant for such Active Ingredient or (ii)
replacement Active Ingredient free of charge. ASL shall pay for all shipping
costs of returning or destroying Active Ingredient that are the subject of such
accepted Claims. ASL shall bear the risk of loss for such Active Ingredient,
beginning at such time as they are taken at Reliant’s premises for return
delivery.

 

(c)           If ASL does not agree with such Claim, then
the parties shall submit the Active Ingredient in question to an independent
party with validated analytical methods (such as Metrics, Inc.) of testing the
Active Ingredient to determine whether or not it complies with the
Specifications. In the event the parties cannot agree upon such independent
party, or in the event it is not possible to acquire the services of such an
independent party, then such dispute shall be resolved pursuant to Section
4.15.

 

SECTION 2.10.      Additional Obligations of
ASL.

 

ASL shall:

 

(a)           Manufacture the Active Ingredient in
accordance with the Specifications and the Quality Agreement for sale to
Reliant taking care to adhere to GMP, and all applicable FDA and other
applicable US laws, rules and regulations including but not limited to the Act
and FDA Guides to Inspections of Bulk Pharmaceutical Chemicals.

 

(b)           Ship all Active Ingredient to Reliant with a
remaining shelf life of at least equal to the approved stability dating as set
forth in the NDA as may be amended from time to time from date of shipment and
perform annual stability testing on the API to support the expiration dating
used on the API and affix lot numbers on the containers of Active Ingredient on
each shipping carton in accordance with applicable US laws. Once expiration
dating of at least thirty six (36) months is assigned to the Active Ingredient,
all Active Ingredient supplied by ASL hereunder will have a remaining shelf
life of at least twenty four (24) months from the date of shipment.

 

(c)           On not less than five (5) business days
notice, afford representatives of Reliant, the FDA and any other United States
authority access to its facilities and that of its subcontractors for the
purpose of inspecting and approving the facilities used to manufacture the
Active Ingredient.

 

(d)           No later than forty five (45) days of
completion of test results on thirty (30) day accelerated stability on the
first validation batch of API, ASL will take all actions necessary to establish
a DMF with FDA as may be required by the rules and regulations of the FDA and
to make all filings necessary to maintain the DMF including, but not limited
to, any necessary updates following the completion of the stability report on
the ninety (90) day accelerated

 

9

 

stability test
on the first validation batch of API. In addition, ASL shall take all action
necessary to provide Reliant with access to the DMF such that the NDA may
reference the DMF for the purposes of this Agreement.

 

(e)           In the event any shipment of the Active
Ingredient fails to conform to the Specifications, GMP, or any applicable FDA
or other US governmental regulation, ASL shall, without charge, promptly
replace any such Active Ingredient with a non-defective, conforming Active
Ingredient. ASL shall promptly investigate the cause of such nonconformance or
defect and shall report back to Reliant with respect to such investigation no
later than seven (7) calendar days after notification or discovery of such
nonconformance or defect.

 

(h)           Neither ASL nor its subcontractors shall
initiate any contact with the FDA or any other US regulatory agency in
connection with the subject matter of this Agreement without the prior written
approval of Reliant. ASL and/or such subcontractor shall inform Reliant, via
same-day telephone and by receipt of written notice within one day thereafter,
of any contacts of ASL or such subcontractor by the FDA or any other US
regulatory agencies in connection with the subject matter of this Agreement,
and ASL or such subcontractor shall prepare and submit to Reliant for its
approval a written record of all such contacts. Reliant shall have the right to
have a representative present at any time the FDA or other US governmental
authority shall elect to conduct an inspection of any site at which a
manufacturing or other investigation of API is being conducted. ASL or such
subcontractor shall forward to Reliant any notice relating to such inspection,
immediately upon receipt thereof.

 

SECTION 2.11.      Adverse Events; FDA
Audits; Etc.

 

(a)           Each party agrees to cooperate with the
other party in the exchange of information concerning Adverse Events associated
with the use in humans of the Products which Reliant or any its Affiliates
manufactures or has manufactured, markets, and distributes from the Active
Ingredient supplied by ASL under this Agreement. Each party shall notify the
designated party of the other set forth in Section 2.13 within one (1) working
day of the Receipt Date. Unless otherwise required by law, Reliant will retain
exclusive authority and responsibility for the reporting of any Adverse Events
to the FDA.

 

(b)           Each party shall notify the designated
Quality Assurance Manager of the other by e-mail, fax or by telephone within
one (1) working day of receipt of any product complaint report received
relating in any manner to the Products which may meet FDA Field-alert Report
criteria codified at 21 CFR 314.81(b)(1)) with an original copy of the report
sent by overnight courier the same day. ASL shall investigate all such
complaints associated with the Active Ingredient and provide a written response
to such complaints with a copy to Reliant. Reliant shall investigate all such
complaints associated with Product (other than complaints associated with the
Active Ingredient)) and provide a written response to the FDA (if required by
applicable laws) to such complaints with a copy to ASL. Each party shall
provide the other with a preview copy of its written responses and consult with
the other regarding such responses prior to filing the responses with the FDA.

 

(c)           Reliant shall have the right to have a
representative present at any time the FDA or other US governmental authority
shall elect to conduct an inspection of any site at which a

 

10

 

manufacturing
or other investigation of the Active Ingredient is being conducted. ASL or such
subcontractor shall forward to Reliant any notice relating to such inspection,
immediately upon receipt thereof.

 

SECTION 2.12.      Product Quality
Complaints.

 

(a)           Complaints that concern any incident that
causes the Product or its labeling to be mistaken for, or applied to, another
article or any bacteriological contamination, or any significant chemical,
physical, or other change or deterioration in the Product, or any failure of
one or more distributed batches of the Product to meet the Specifications shall
be telephoned to both parties promptly upon receipt.

 

(b)           The relevant contact person with respect to
Adverse Events shall be:

 

	
   

  	
  If to ASL:

  
	
   

  	
   

  
	
   

  	
  Facsimile No.:  (847) 520 9160

  
	
   

  	
  Telephone No.:  (847) 520 9600

  
	
   

  	
  E-mail:                @austinchemical.com

  
	
   

  	
   

  
	
   

  	
  If to Reliant:  Reliant Medical Affairs

  
	
   

  	
   

  
	
   

  	
  Fax:

  	
  1-877-311-8160

  
	
   

  	
  Tel:

  	
  1-908-580-1200

  
	
   

  	
   

  	
  1-877-311-7515

  

 

SECTION 2.13.      Government Agency Recalls.

 

(a)           Each of the parties agree to maintain or
cause to be maintained such traceability records as are necessary to permit a
recall, withdrawal, field alert or field correction of Active Ingredient or
Product.

 

(b)           In the event any governmental agency having
applicable jurisdiction shall order any corrective action with respect to
Product containing Active Ingredient supplied hereunder such as customer
notice, restriction, change, corrective action or market action or any Product
change, and the cause of basis of such corrective action is due to the actions
or inactions of ASL under this Agreement including without limitation the
failure of the API to meet the Specifications or a breach by ASL of Section
3.1(a) below, then ASL shall be liable to Reliant to credit or replace such API
as required by Section 2.9(b), including paying all costs of returning or
destroying such API.

 

(c)           Reliant shall have the right to determine
that a recall of any portion of Product is necessary or appropriate at any
time, and to design, administer and control the recall process (provided, however,
that at the request of ASL, ASL shall have the right to consult with Reliant
prior to determining that a recall is necessary). If a recall is determined to
be necessary or appropriate due to ASL’s breach of any of its obligations under
this Agreement, ASL shall be

 

11

 

liable for
replacing the Active Ingredient used to manufacture the recalled Product. For
purposes of this Section, “recall” means a firm’s removal or correction (e.g.,
repair, modification, adjustment, re-labeling, destruction or inspection
(including patient/consumer marketing) of a product without its physical
removal to some other location) of a marketed Product that there are reasonable
grounds to believe could be considered by the FDA to be in violation of the Act
or against which the FDA could initiate legal action.

 

SECTION 2.14.      Annual Review. The
parties agree to establish an annual business review process pursuant to which
the parties will review (either in person, by telephone, videoconference or
other mutually agreeable means) Active Ingredient quality, cycle time,
manufacturing capacity, projected market needs, and delivery.

 

SECTION 3

 

GENERALLY APPLICABLE TERMS

 

SECTION 3.1.        Representations and
Warranties.

 

(a)           ASL to the best of its knowledge represents
and warrants to Reliant that:

 

(i)         the Active IngredientS
supplied by ASL will be manufactured in accordance with the Specifications GMP,
the DMF and all applicable FDA and other US governmental regulations;

 

(ii)        the Active Ingredient
supplied by ASL are being sold to Reliant free and clear of all liens, claims
and encumbrances of any nature;

 

(iii)       attached as Exhibit C is a
true and correct copy of the Quality Agreement as executed by the parties;

 

(iv)       to the best of its knowledge
after diligent inquiry, the Active Ingredient, and its manufacture or use by
ASL, does not violate any patents, patent rights, patent applications,
inventions, copyrights, confidential information, trade secrets, proprietary
rights or processes of any other person in the country where such Active
Ingredient is manufactured or in the Territory;

 

(v)        there are no pending or
threatened suits, claims, or actions of any type whatsoever against ASL with
respect to the Active Ingredient or the manufacture thereof;

 

(vi)       all necessary corporate and
other authorizations including all necessary approvals, licenses and
authorizations from FDA or other US governmental entities, consents and
approvals which are necessary or required for ASL to enter into this Agreement
have been duly obtained and are in and will remain in full force and effect;

 

(vii)      the entering into of this
Agreement (including the Quality Agreement) by ASL will not (i) violate any
provision of law, statute, rule or regulation or any ruling, writ, injunction,
order, judgment or decree of any court, administrative agency or other
governmental body or (ii) conflict with or result in any breach of any of the
terms,

 

12

 

conditions or
provisions of, or constitute a default (or give rise to any right of
termination, cancellation or acceleration) under, or result in the creation of
any lien, security interest, charge or encumbrance upon any of the properties
or assets of ASL, under its organizational documents, as amended to date, or
any material note, indenture, mortgage, lease, agreement (including the Quality
Agreement), contract, purchase order or other instrument, document or agreement
to which ASL is a party or by which it or any of its properties or assets is
bound or affected;

 

(viii)     ASL shall, and shall cause
its Affiliates, subcontractors, joint venture partners, and any other person or
entity performing services under this Agreement to, comply with all applicable
United States laws, rules and regulations applicable to their manufacture or
sale of the Active Ingredient (this warranty does not and is not intended to
address third party proprietary rights); and

 

(ix)       ASL has not been debarred
and ASL has not and will not use in any capacity in connection with the
performance of its obligations under this Supply Agreement the services of any
individual or person known by ASL to be debarred in each case by the FDA under
the provisions of the Generic Drug Enforcement Act of 1992, as amended, or
other applicable

 

The foregoing warranties extend only to
Reliant and its Affiliates, contract manufacturers, corporate partners and/or
other persons who collaborate with Reliant in the production of Product from
the Active Ingredient. THE FOREGOING WARRANTIES SHALL NOT COVER AND ASL MAKES
NO WARRANTIES WITH RESPECT TO: (A) ANY ACTIVE INGREDIENT THAT HAS BEEN SUBJECT
TO; (I) ABUSE, MISUSE, MISAPPLICATION, NEGLECT, ALTERATION OR ACCIDENT AFTER
DELIVERY AND ACCEPTANCE OF THE API BY RELIANT: (II) IMPROPER OR INCORRECT STORAGE
AFTER DELIVERY AND ACCEPTANCE BY RELIANT; OR (; OR (III) ANY MATERIALS, PARTS,
GOODS OR OTHER COMPONENTS NOT SUPPLIED BY ASL WHICH ARE USED BY RELIANT IN
CONNECTION WITH THE PRODUCT.

 

(b)           Reliant represents and warrants to ASL that:

 

(i)         all necessary corporate
and other authorizations, consents and approvals which are necessary or
required for Reliant to enter into this Agreement have been duly obtained;

 

(ii)        the entering into of this
Agreement (including the Quality Agreement) by Reliant will not (i) violate any
provision of law, statute, rule or regulation or any ruling, writ, injunction,
order, judgment or decree of any court, administrative agency or other
governmental body or (ii) conflict with or result in any breach of any of the
terms, conditions or provisions of, or constitute a default (or give rise to
any right of termination, cancellation or acceleration) under, or result in the
creation of any lien, security interest, charge or encumbrance upon any of the
properties or assets of Reliant under its organizational documents, as amended
to date, or any material note, indenture, mortgage, lease, agreement, contract,
purchase order or other instrument, document or

 

13

 

agreement in
which Reliant is a party or by which it or any of its properties or assets is
bound or affected;

 

(iii)       Reliant shall not, during
the course of any manufacturing, marketing or selling by it of the Products,
engage in any act which results in the Products being adulterated or misbranded
within the meaning of the Act, or any regulation promulgated thereunder;

 

(iv)       Reliant shall comply with
all applicable laws, rules and regulations applicable to their importation,
manufacture, use or sale of the Product in the Territory;

 

(v)        To the best of its
knowledge, the Product, and its manufacture, use or sale by Reliant and/or its
Affiliates, will not violate any patents, patent rights, patent applications,
inventions, copyrights, confidential information, trade secrets, proprietary rights
or processes of any other person;

 

(c)           THE WARRANTIES CONTAINED IN THIS SECTION 3.1
ARE THE EXCLUSIVE WARRANTIES MADE BY THE PARTIES IN RESPECT OF THE ACTIVE
INGREDIENT AND PRODUCT, AND ALL OTHER WARRANTIES RELATING THERETO, EXPRESS,
STATUTORY OR IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF FITNESS FOR A
PARTICULAR PURPOSE, AND MERCHANTABILITY ARE HEREBY WAIVED AND EXCLUDED;
PROVIDED HOWEVER THAT NOTHING IN THIS SECTION 3.1 SHALL BE DEEMED OR CONSTRUED
TO LIMIT ASL’s OBLIGATIONS UNDER SECTION 2.10.

 

SECTION 3.2.        Indemnification. In
order to distribute among themselves the responsibility for claims arising out
of this Agreement, and except as otherwise specifically provided for herein,
the parties agree as follows:

 

(a)           ASL shall defend and indemnify and hold
Reliant (and its Affiliates, and their respective officers, directors and
employees) harmless against any and all claims, suits, proceedings, expenses,
recoveries and damages, including court costs and reasonable attorneys fees and
expenses (collectively, “Losses”), arising out of, based on, or caused by (A)
the breach by ASL of any representation or warranty contained in this
Agreement, (B) any failure of ASL to comply with any applicable US law in
connection with performing its obligations under this Agreement or (C) any
negligence or intentional misconduct by ASL in connection with performing its
obligations under this Agreement in each case except to the extent that such
Losses arise from or are aggravated by the grossly negligent acts of or failure
to act by Reliant or its Affiliates. Reliant will promptly notify ASL of any
such Losses which come to its attention.

 

(b)           Reliant shall defend and indemnify and hold
ASL (and its Affiliates, and their respective officers, directors and employees)
harmless against any and all Losses, arising out of, based on, or caused by (A)
statements, whether written or oral, made or alleged to be made by Reliant or
its Affiliates on the packaging or labeling of any of the Products, or in the
advertising, manufacturing (other than the manufacturing of the Active
Ingredient), promotion, use or sale of any of the Products, (B) the storage,
sale, shipment, promotion or distribution of the Products by Reliant or its
Affiliates, or (C) the breach by Reliant of any representation or warranty
contained

 

14

 

in this
Agreement, in each case except to the extent that such Losses arise from or are
aggravated by the grossly negligent acts of or failure to act by ASL or its Affiliates.
ASL will promptly notify Reliant of any such Losses which comes to its
attention.

 

(c)           In the event either party becomes aware of
any product liability claims from third parties with respect to the Products
(whether related to the safety or efficacy of the Product, or arising out of
alleged defects in materials, design or workmanship of the Product or
otherwise, (hereinafter, a “Product Liability Claim”), it shall promptly notify
the other of such matter, and provide copies of any notices, claims, letters or
other information which such party has received or possesses in connection with
such Product Liability Claim. Each party shall reasonably cooperate with the
other with respect to the defense and resolution of any such Product Liability
Claim. Reliant shall have responsibility for controlling any litigation,
defense or settlement of any such Product Liability Claims.

 

SECTION 3.3.        Infringement
Indemnification.

 

(a)           ASL shall defend and indemnify and hold
Reliant (and its Affiliates and the respective officers, directors and
employees) harmless against any and all claims, suits, proceedings, expenses,
recoveries and damages, including court costs and reasonable attorneys fees and
expenses arising from or relating to claims that the formulation or manufacture
of Active Ingredient or other activities of ASL under this Agreement infringe
on the patent or other intellectual property rights of a third party within the
Territory.

 

(b)           Reliant shall defend and indemnify and hold
ASL (and its Affiliates and the respective officers, directors and employees)
harmless against any and all claims, suits, proceedings, expenses, recoveries
and damages, including court costs and reasonable attorneys fees and expenses
arising from or relating to claims that the Products manufactured using the API
supplied or its use or sale infringes on the patent or other intellectual
property rights of a third party.

 

SECTION 3.4.        Insurance.

 

(a)           Reliant and ASL shall each at its own
expense obtain and maintain insurance of the type and amount described in
Section 3.4(b). Neither party shall do or omit to do any act, matter or thing
which could prejudice or render voidable any such insurance.

 

(b)           The parties agree that each will maintain
during the performance of this Agreement the following insurance in amounts no
less than that specified for each type:

 

(i)         General liability
insurance with combined limits of not less than $1,000,000 per occurrence and
$1,000,000 per accident for bodily injury, including death and property damage.

 

(ii)        product liability
insurance with combined limits of not less than $3,000,000 per occurrence and
$3,000,000 per accident for bodily injury, including death and property damage.

 

15

 

(c)           Each party will provide to the other party
evidence of its insurance naming the other as an additional insured and
containing a waiver of subrogation against the other and thirty (30) days prior
written notice of any cancellation of its coverage or reduction in coverage from
the requirements stated herein.

 

SECTION 3.5.        Term.

 

(a)           This Agreement shall remain in effect from
the Effective Date for a period of seven (7) years from the receipt of the
first Regulatory Approval for either of the Initial Products (the “Initial Term”).
Unless sooner terminated, this Agreement shall be renewed automatically for
successive terms of two (2) years unless either party provides notice to the
contrary within one hundred twenty (120) days prior to the end of the Initial
Term or any such additional term.

 

(b)           Notwithstanding any other provision of this
Agreement, either Reliant or ASL may terminate this Agreement by notice in
writing to the other upon the occurrence of any of the following events:

 

(i)         if the other commits a
breach of this Agreement (other than a breach by Reliant of Section 2.8 hereof)
that the notified party fails to remedy within thirty (30) days of the receipt
by the other of a notice identifying the breach and requiring its remedy; or

 

(ii)        if the other is subject to
a Bankruptcy Event.

 

(c)           Reliant may terminate this Agreement
immediately upon written notice to ASL if:

 

(i)         the FDA prohibits the
Product(s) from being manufactured, shipped, sold or marketed, in which event
all outstanding or unfinished purchase orders (including any firm order
obligations pursuant to any forecasts) shall be cancelled;

 

(ii)        in the absence of a force
majeure event under Section 4.10 below, ASL is unable to supply API in
sufficient quantities to meet purchase orders submitted in accordance with
Section 2.8 hereunder for a period of six (6) months in any twelve (12) month
period or, taking into account any such force majeure event, ASL is unable to
meet such purchase orders for a continuous period of six (6) months; or

 

(iii)       any representation or
warranty made herein by ASL proves to be incorrect in any material respect when
made.

 

(d)           ASL may terminate this Agreement upon
written notice to Reliant if any representation or warranty made herein by
Reliant proves to be incorrect in any material respect when made.

 

SECTION 3.6.        Effect of Termination.

 

(a)           If this Supply Agreement is terminated for
any reason other than Reliant’s failure to make payment under this Agreement,
ASL shall complete the manufacture of any binding

 

16

 

purchase order
for Active Ingredient and ship such Active Ingredient pursuant to the terms of
this Agreement.

 

(b)           The termination or expiration of this
Agreement will not release either party from the obligation to pay any sum that
may be owing to the other party (whether then or thereafter due) to operate any
liability or obligation that had been incurred by either Party prior to any
such termination.

 

SECTION 4

 

MISCELLANEOUS

 

SECTION 4.1.        Confidentiality; Press
Releases.

 

(a)           Reliant and ASL will be exchanging
confidential and proprietary information relating to the Active Ingredient and
Products and their respective businesses at the inception of and from time to
time during the term of this Agreement. The party receiving such information
will maintain the information in confidence using the same standard of care it
uses to maintain its own information in confidence. Such obligation of
confidentiality shall not apply to information which (i) is known to the
receiving party prior to the disclosure, (ii) is publicly known as of the date
of the disclosure, (iii) becomes publicly known after the date of disclosure
through no fault of the receiving party, (iv) is received from a third party
who has no obligation of confidentiality to the disclosing party or (v) is
developed independently by or for the receiving party. Such obligation of
confidentiality shall continue for a period of five (5) years from the date of
termination of this Agreement.

 

(b)           Notwithstanding the foregoing Section
4.1(a), (i) Reliant shall be permitted to disclose to its manufacturers,
subcontractors, wholesalers, other direct customers, investment bankers and/or
financing sources such confidential information relating to the Products and
this Agreement as Reliant shall reasonably determine to be necessary in order
to effectively market and distribute the Products or otherwise engage in a bona
fide financing transaction and (ii) ASL shall be permitted to disclose to its
Affiliates, manufacturers, subcontractors, wholesalers, other direct customers,
investment bankers and/or financing sources such confidential information
relating to the Active Ingredient and Products as ASL may reasonably determine
to be necessary to perform its obligations under this Agreement, provided that
such entities undertake the same confidentiality obligation as the disclosing
party has with respect to the other’s confidential information and provided
that ASL and its Affiliates may disclose the fact of the Agreement for purposes
of marketing its services.

 

(c)           Except as may be required by applicable
laws, rules or regulations (including in connection with a public offering of
securities), neither party will originate any publicity, news release, or other
public announcement, written or oral, whether to the public press or otherwise,
relating to this Agreement, any amendment hereto or to performance hereunder,
or the existence of an arrangement between the parties, without the prior
written approval of the other party, which consent shall not be unreasonably
withheld or delayed (it being understood that such obligation is not intended
to restrict either party’s ability to promote, market and sell the Products or
its services in a commercially reasonable manner). In the event disclosure is

 

17

 

required by
applicable law, rules or regulations, then the party required to so disclose
such information shall, to the extent possible, provide to the other party for
its approval (such approval not to be unreasonably withheld) a written copy of
such public announcement at least ten (10) business days prior to disclosure. In
the absence of a communication approving or disapproving of the public
announcement from the party with the right of approval by the end of such ten
(10) day period, such party shall be deemed to have approved the public
announcement.

 

SECTION 4.2.        Survival. Those
provisions of this Agreement dealing with rights and obligations upon and/or
after termination of this Agreement including but not limited to Sections 1.1
(to the extent necessary to give effect to the Articles and Sections enumerated
in this Section 4.2), 2.6, 2.7(d), 2.8(d), 2.8(e), 2.8(f), 2.10, 2.11.2.12,
2.13, 3.2, 3.3, 3.4, 3.6, 4.3, 4.9, 4.15, 4.16 and 4.17 shall survive termination
of this Agreement to the extent necessary to give effect to such provisions.

 

SECTION 4.3.        Penalties. If
either party terminates this Agreement in accordance with the terms herein the
terminating party shall owe no penalty to the terminated party on account of
such termination.

 

SECTION 4.4.        Independent Contractor
Status. Neither party shall have any authority to obligate the other in any
respect nor hold itself out as having any such authority. All personnel of ASL
shall be solely employees of ASL and shall not represent themselves as
employees of Reliant, and all personnel of Reliant shall be solely employees of
Reliant and shall not represent themselves as employees of ASL.

 

SECTION 4.5.        Binding Effect;
Benefits. This Agreement shall endure to the benefit of and be binding upon
the parties and their respective permitted successors and assigns. Nothing
contained herein shall give to any other person any benefit or any legal or
equitable right, remedy or claim.

 

SECTION 4.6.        Assignment.

 

Neither party may assign this Agreement or
any of its rights hereunder or delegate its performance of its obligations
hereunder without the express prior written consent of the other party, except
that either party may assign or delegate any of its rights or obligations under
this Agreement to an Affiliate or subsidiary; provided that the assigning party
shall be made liable for all obligations and liabilities of the assignee
following such assignment. Notwithstanding the foregoing (a) each party may
assign this Agreement to any purchaser of all or substantially all of its
assets or to any successor entity resulting from any merger or consolidation of
such party with or into such entity AND (b) Reliant may assign its rights and
obligations hereunder to an acquirer of all or substantially all of Reliant’s
assets relating to one or more of the Products. The (i) conversion of either
party from a limited liability company to a corporation and/or (ii) issuance by
either party of securities in connection with any financing transaction or
public offering shall not be deemed an assignment and shall be permitted
without notice to or consent from the other party or its Affiliates. My
attempted assignment in violation of this provision shall be deemed a material
breach of this Agreement.

 

18

 

SECTION 4.7.        Entire Agreement;
Amendments. The parties acknowledge that this Agreement sets forth the
entire agreement and understanding of the parties as to the subject matter of
this Agreement, and supersedes any prior verbal, written or other
understandings of the parties with respect to the subject matter of this
Agreement. This Agreement shall not be subject to any change or modification
except by the execution of a written instrument subscribed to by the parties. To
the extent of any conflict or inconsistency between this Agreement and any
purchase order, purchase order release, confirmation, acceptance or any similar
document, the terms of this Agreement shall govern.

 

SECTION 4.8.        Severability. In
the event that any provision of this Agreement would be held in any
jurisdiction to be invalid, prohibited or unenforceable for any reason, such
provision, as to such jurisdiction, shall be ineffective, without invalidating
the remaining provisions of this Agreement or affecting the validity or
enforceability of such provision in any other jurisdiction. Notwithstanding the
foregoing, if such provision could be more narrowly drawn so as not to be
invalid, prohibited or unenforceable in such jurisdiction, it shall, as to such
jurisdiction, be so narrowly drawn, without invalidating the remaining
provisions of this Agreement or affecting the validity or enforceability of
such provision in any other jurisdiction.

 

SECTION 4.9.        Remedies; Etc. Unless
otherwise expressly provided, all remedies hereunder are cumulative, are in
addition to any other remedies provided for by law and may, to the extent
permitted by law, be exercised concurrently or separately, and the exercise of
any one remedy shall not be deemed to be an election of such remedy or to
preclude the exercise of any other remedy.

 

SECTION 4.10.      Force Majeure.

 

The obligations of ASL and Reliant hereunder
shall be subject to any delays or non-performance caused by acts of God,
earthquakes, fires, floods, explosion, sabotage, riot, accidents; orders of, or
failure to issue all necessary permits or licenses by, regulatory,
governmental, or military authorities; strikes, lockouts or labor trouble;
perils of the sea; or any other similar cause beyond the reasonable control of
either party, and each party shall be under no liability to the other for
anything which would constitute a breach of this Agreement arising by reason of
such matters. The party which is not performing its obligations under this Agreement
as a result of an event of force majeure shall use diligent efforts to resume
compliance with this Agreement as soon as possible. Should the event of force
majeure continue unabated for a period of sixty (60) days or more, the parties
shall enter into good faith discussions with a view to alleviating its affects
or to agreeing upon such alternative arrangements as may be fair and reasonable
having regard to the circumstances prevailing at that time. In the event that
such alternative arrangements cannot be agreed upon within thirty (30) days
after the expiration of such initial sixty (60) day period, then the
non-performing party shall continue to diligently attempt to alleviate such
event of force majeure until it is removed or eliminated.

 

SECTION 4.11.      Notices. Any notice,
request, consent or communication (collectively, a “Notice”) under this
Agreement shall be effective if it is in writing and (i) personally delivered,
(ii) sent by certified or registered mail, postage prepaid, return receipt
requested, (iii) sent by an internationally recognized overnight delivery
service, with delivery confirmed, or (iv) e-mail,

 

19

 

telexed or
facsimile, with receipt confirmed, addressed as set forth in this Section or to
such address as shall be furnished by either party hereto to the other party
hereto. A Notice shall be deemed to have been given as of (i) the date when
personally delivered, (ii) five (5) business days after being deposited with
the United States Postal Service, certified or registered mail, properly
addressed, return receipt requested, postage prepaid, (iii) one business day
after being delivered to said overnight delivery service properly addressed, or
(iv) confirmation of receipt of the e-mail, telex or facsimile, as the case may
be. All Notices shall specifically state: (i) the provision (or provisions) of
this Agreement with respect to which such Notice is given, and (ii) the
relevant time period, if any, in which the party receiving the Notice must
respond.

 

	
   

  	
  If to ASL:

  	
  Austin Shasun LLC

  
	
   

  	
   

  	
  1565 Barclay Boulevard

  
	
   

  	
   

  	
  Buffalo Grove, IL 60089-4537

  
	
   

  	
   

  	
  Attn:                    

  
	
   

  	
   

  	
   

  
	
   

  	
  Facsimile: (847) 520 9160

  
	
   

  	
  E-mail:                  @austinchemical.com

  
	
   

  	
   

  	
   

  
	
   

  	
  Telecopier:

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  if to Reliant to:

  	
  Reliant Pharmaceuticals, LLC

  
	
   

  	
   

  	
  110 Allen Road

  
	
   

  	
   

  	
  Liberty Corner, New Jersey 07938

  
	
   

  	
   

  	
  Attn: Joseph Krivulka, President

  
	
   

  	
   

  	
   

  
	
   

  	
  Telephone:

  	
  (908) 542-4400

  
	
   

  	
  Fax:

  	
  (908) 542-9406

  
	
   

  	
   

  	
   

  
	
   

  	
  with a copy to:

  	
  Reliant Pharmaceuticals, LLC

  
	
   

  	
   

  	
  110 Allen Road

  
	
   

  	
   

  	
  Liberty Corner, New Jersey 07938

  
	
   

  	
   

  	
  Attn: Michael J. Lerner, General Counsel

  
	
   

  	
   

  	
   

  
	
   

  	
  Telephone:

  	
  (908) 542-4408

  
	
   

  	
  Fax:

  	
  (908) 542-9406

  
					

 

SECTION 4.12.      Waivers. The failure
of either party to assert a right hereunder or to insist upon compliance with
any term or condition of this Agreement shall not constitute a waiver of that
right or excuse a similar subsequent failure to perform any such term or
condition by the other party.

 

SECTION 4.13.      Counterparts. This
Agreement may be executed in any number of counterparts, and execution by each
of the parties of any one of such counterparts will constitute due execution of
this Agreement. Each such counterpart shall be deemed to be an original
instrument, and all such counterparts together shall constitute but one
agreement.

 

20

 

SECTION 4.14.      Headings. The article
and section headings contained in this Agreement are for reference purposes
only and shall not affect in any way the meaning or interpretation of this
Agreement.

 

SECTION 4.15.      Governing Law; Dispute
Resolution.

 

(a)           This Agreement shall be construed, governed,
interpreted and applied in accordance with the laws of the State of New York,
U.S.A. without regard to the conflict of law principles thereof, and the United
Nations Convention on Contracts for the International Sale of Goods is
expressly disclaimed.

 

(b)           Excepting only actions and claims relating
to actions commenced by a third party against ASL or Reliant (including,
without limitation, actions for injuries caused by a Product, or in respect to
a patent infringement claim), any controversy or claim arising out of or
relating to this Agreement, or the parties’ decision to enter into this
Agreement, or the breach thereof, shall be settled by arbitration in accordance
with the arbitration American Arbitration Association, and judgment upon the
award rendered by the arbitrator may be entered in any court having
jurisdiction thereof.

 

(c)           The arbitration shall be held before a
single arbitrator, to be selected by ASL and Reliant or, if ASL and Reliant
cannot agree on such arbitrator, in accordance with the applicable arbitration
rules provided that the arbitrator shall have significant pharmaceutical
manufacturing and supply experience. Arbitration shall be in the State of New
York and the arbitrator shall apply the substantive law of the State of New
York. It shall be the duty of the arbitrator to set dates for preparation and
hearing of any dispute and to expedite the resolution of such dispute. The
arbitrator shall permit and facilitate discovery, taking into account the needs
of the parties and the desirability of making discovery expeditious and
cost-effective. The arbitrator will set a discovery schedule with which the
parties will comply and attend depositions if requested by either party. The
arbitrator will entertain such presentation of sworn testimony or evidence,
written briefs and/or oral argument as the parties may wish to present;
however, no testimony or exhibits will be admissible unless the adverse party
was afforded an opportunity to examine such witness and to inspect and copy
such exhibits during the pre-hearing discovery phase. The arbitrator shall
among his other powers and authorities, have the power and authority to award
interim or preliminary relief.

 

(d)           The arbitrator shall not award either
parties punitive damages and the parties shall be deemed to have waived any
right to such damages. A qualified court reporter will record and transcribe
the proceedings. The decision of the arbitrator will be in writing and judgment
upon the award by the arbitrator may be entered into any court having
jurisdiction thereof. Prompt handling and disposal of the issue is important. Accordingly,
the arbitrator is instructed to assume adequate managerial initiative and control
over discovery and other aspects of the proceeding to schedule discovery and
other activities for substantially continuous work, thereby expediting the
arbitration as much as is deemed reasonable to him, but in all events to effect
a final award within three hundred sixty five (365) days of the arbitrator’s
selection or appointment and within twenty (20) days of the close of evidence.

 

21

 

(e)           The proceedings shall be confidential and
the arbitrator shall issue appropriate protective orders to safeguard both
parties’ confidential information. The fees of the arbitrator shall be paid by
the losing party, which shall be designated by the arbitrator. If the
arbitrator is unable to designate a losing party, he shall so state and the
fees shall be split equally between the parties.

 

(f)            Each party is required to continue to
perform its obligations under this Agreement pending final resolution of any
such dispute.

 

(g)           The procedures specified in this Section 4.15
shall be the sole and exclusive procedures for the resolution of disputes
between the parties arising out of or relating to this Agreement; provided
however, that a party, without prejudice to the above procedures, may seek
injunctive relief or other provisional judicial relief, if in its sole
judgment, such action is necessary to avoid irreparable damage.

 

SECTION 4.16.      Consequential Damages.
Neither Reliant nor ASL (which for the purposes of this Section 4.16 shall
include their respective Affiliates, directors, managers, officers, employees,
consultants, equity holders, representatives and agents) shall have any
liability to the other for any punitive damages, specialty, incidental,
consequential or indirect damage relating to or arising from the loss of
commercial or business opportunity, revenue or profit, in connection with or
arising out of this Agreement even if such damages may have been forecasted;
providing that such limitations shall not apply in the case of (a) fraud, (b)
intentional misconduct or (c) any damages claimed by or paid to a third party
in a third party action.

 

SECTION 4.17.      Limitation of Liability.
Except in the cases of fraud, gross negligence or intentional misconduct ASL’s
aggregate liability to Reliant under this Agreement for any calendar year
during the term of this Agreement shall not exceed the net amounts paid by
Reliant (amounts paid less the Annual Payment Amount rebated) under Section 2.7
above with respect to that calendar year.

 

SECTION 4.18       Conversion to Non-Exclusive. Following the Initial Period, in
the event that Reliant fails to purchase the Minimum in any two (2) consecutive
calendar quarters pursuant to Section 2.8 hereof, ASL as its sole remedy
hereunder shall on thirty (30) days written notice shall be relieved of the
restriction on sales to third parties of Active Ingredient set forth in Section
2.1(b) hereof. Reliant, however, shall have the option during the thirty days
following notice from ASL to purchase such amounts of API as necessary to
satisfy the Minimum for the calendar quarters in question in which case the
restriction on sales of Active Ingredient to third parties set forth in Section
2.1(b) shall remain in full force and effect.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

22

 

IN WITNESS WHEREOF, duly authorized
representatives of the parties hereto have duly executed this Agreement as of
the date first above written.

 

	
   

  	
  RELIANT PHARMACEUTICALS, LLC

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
  Title:

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  AUSTIN SHASUN, LLC

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
  Title:

  

 

23

 

Exhibit A

 

SPECIFICATIONS

 

[TO BE SUPPLIED]

 

24

 

Exhibit A

 

Isradipine API Specifications

 

	
   

  	
   

  	
  Tests

  	
   

  	
  Limits

  
	
  1

  	
   

  	
  [***]

  	
   

  	
  [***]

  
	
  2

  	
   

  	
  [***]

  	
   

  	
  [***]

  
	
  3

  	
   

  	
  [***]

  	
   

  	
  [***]

  
	
  4

  	
   

  	
  [***]

  	
   

  	
  [***]

  
	
  5

  	
   

  	
  [***]

  	
   

  	
  [***]

  
	
  6

  	
   

  	
  [***]

  	
   

  	
  [***]

  
	
  7

  	
   

  	
  [***]

  	
   

  	
  [***]

  
	
  8

  	
   

  	
  [***]

  	
   

  	
  [***]

  
	
  9

  	
   

  	
  [***]

  	
   

  	
  [***]

  
	
  10

  	
   

  	
  [***]

  	
   

  	
  [***]

  
	
  11

  	
   

  	
  [***]

  	
   

  	
  [***]

  

 

[***]:  Certain information on this page has been
omitted and filed separately with the Commission.  Confidential treatment has been requested
with respect to the omitted portions.

25

 

Exhibit B

 

Pricing

 

The purchase
price (“Purchase Price”) for Active Ingredient purchased from ASL shall be as follows:

 

Non-Commercial
Use – $[***]

 

Commercial
Use:

 

	
  Kilos Purchased (Annualized)

  	
   

  	
  Cost/Kg

  
	
  Tier 1

  	
  [***]

  	
   

  	
  $[***]

  
	
  Tier 2

  	
  [***]

  	
   

  	
  $[***]

  
	
  Tier 3

  	
  [***]

  	
   

  	
  $[***]

  

 

[***]:  Certain information on this page has been
omitted and filed separately with the Commission.  Confidential treatment has been requested
with respect to the omitted portions.

 

26

 

Exhibit C

 

QUALITY AGREEMENT

 

 

27

 

COMMERCIAL

QUALITY AGREEMENT

 

 

Between

 

 

And

 

SHASUN CHEMICALS AND DRUGS LTD.

 

 

For the manufacture of:

 

Nizatidine Active Pharmaceutical Ingredient

DMF # 13192

 

 

TABLE OF CONTENTS

 

	
   

  	
   

  	
  Page

  
	
   

  	
   

  	
   

  
	
  I

  	
  QUALITY AGREEMENT AND TERM

  	
  1

  
	
   

  	
   

  	
   

  
	
  II

  	
  PRODUCTS

  	
  1

  
	
   

  	
   

  	
   

  
	
  III

  	
  CONTACT INFORMATION

  	
  1

  
	
   

  	
   

  	
   

  
	
  IV

  	
  MANUFACTURING COMPLIANCE

  	
  2

  
	
   

  	
  1.

  	
  Premises

  	
  2

  
	
   

  	
  2.

  	
  Equipment

  	
  2

  
	
   

  	
  3.

  	
  Personnel

  	
  2

  
	
   

  	
  4.

  	
  Materials

  	
  3

  
	
   

  	
  5.

  	
  Documentation

  	
  3

  
	
   

  	
  6.

  	
  Lot Numbers and Expiration

  	
  4

  
	
   

  	
  7.

  	
  Product Storage and Shipment

  	
  4

  
	
   

  	
   

  	
   

  
	
  V

  	
  QUALITY CONTROL

  	
  4

  
	
   

  	
  1.

  	
  Premises

  	
  4

  
	
   

  	
  2.

  	
  Equipment

  	
  5

  
	
   

  	
  3.

  	
  Vendor Approval

  	
  5

  
	
   

  	
  4.

  	
  Personnel

  	
  5

  
	
   

  	
  5.

  	
  Out-of-Specification (OOS)
  Investigations

  	
  5

  
	
   

  	
  6.

  	
  Reference Standards

  	
  5

  
	
   

  	
  7.

  	
  Product Release

  	
  5

  
	
   

  	
  8.

  	
  Stability

  	
  5

  
	
   

  	
   

  	
   

  
	
  VI

  	
  QUALITY ASSURANCE

  	
  6

  
	
   

  	
  1.

  	
  Documentation

  	
  6

  
	
   

  	
  2.

  	
  Samples

  	
  6

  
	
   

  	
  3.

  	
  Change Control

  	
  6

  
	
   

  	
  4.

  	
  Product Complaints or Adverse
  Events

  	
  7

  
	
   

  	
  5.

  	
  Product Quality Review

  	
  7

  
	
   

  	
  6.

  	
  Product Recalls

  	
  8

  
	
   

  	
  7.

  	
  Audits by Reliant
  Pharmaceuticals

  	
  8

  
	
   

  	
   

  	
   

  
	
  VII

  	
  REGULATORY

  	
  8

  
	
   

  	
  1.

  	
  Inspections by Regulatory
  Agencies

  	
  8

  
	
   

  	
  2.

  	
  Annual Reports

  	
  9

  
	
   

  	
  3.

  	
  Drug Listing

  	
  9

  
	
   

  	
   

  	
   

  
	
  VIII

  	
  VALIDATION

  	
  9

  
	
   

  	
  1.

  	
  Process

  	
  9

  
	
   

  	
  2.

  	
  Equipment Cleaning Validation

  	
  9

  
	
   

  	
  3.

  	
  Analytical Test Methods

  	
  10

  
	
   

  	
  4.

  	
  Computer

  	
  10

  
	
   

  	
   

  	
   

  
	
  IX

  	
  REVISION HISTORY AND APPROVAL

  	
  11

  

 

i

 

I               QUALITY
AGREEMENT AND TERM

 

1.                                       It
is deemed necessary by Reliant Pharmaceuticals, Inc. (“Reliant”) and Shasun
Chemicals and Drugs Ltd. (“Shasun”) to allocate the responsibilities of current
good manufacturing practice (cGMP), as defined in ICH Guidance for Industry Q7A
Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients, and
FDA Guide for Manufacturing, Processing and Holding APIs, by which Nizatidine
API shall be manufactured and provided to Reliant.

 

2.                                       This
agreement, in conjunction with the Supply Agreement between Reliant and Shasun,
dated August 4, 2004 (the “Supply Agreement”), shall define the
responsibilities of the panties involved, and the levels of interaction
necessary for the delivery of compliant product.

 

3.                                       This
Quality Agreement shall expire with the termination of the Supply Agreement.
The Quality agreement can be modified with the written approval of Reliant and
Shasun. Such revisions shall supercede previous quality commitments in the
Supply Agreement. A revision history shall be maintained as part of the Quality
Agreement.

 

II             PRODUCTS

 

Shasun has
agreed to manufacture Nizatidine API in accordance with all cGMP’s, Product
Specifications and all applicable federal, state, and local laws and
regulations.

 

III            CONTACT
INFORMATION

 

Communication
pertaining to the manufacture of the Product shall flow between the established
channels detailed below.

 

	
  DEPARTMENT

  	
   

  	
  RELIANT CONTACT

  	
   

  	
  SHASUN CONTACT

  
	
  QUALITY

  	
   

  	
  Name

  Phone

  Fax

  e-mail

  	
  Keith
  Bowen

  (908) 542-4432

  (908) 542-4460

  kbowen@reliantrx.com

  	
   

  	
  Name

  Phone

  Fax

  e-mail

  	
  v.Rajasekaran
  / V. Sundaramoorthy

  00 91 44 22452864

  00 91 44 22452462

  vrajasekaran@shasun.com

  moorthy@shasun.com

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  OPERATIONS

  	
   

  	
  Name

  Phone

  Fax

  e-mail

  	
  Christopher
  Campbell

  (908) 542-4425

  (908) 542-9405

  ccampbell@reliantrx.com

  	
   

  	
  Name

  Phone

  Fax

  e-mail

  	
  A.Chandrasekar

  

  

  chandru@shasun.com

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  REGULATORY

  	
   

  	
  Name

  Phone

  Fax

  e-mail

  	
  Paulette Kosmoski

  (908) 542-4403

  (908) 542-4460

  pkosmoski@reliantrx.com

  	
   

  	
  Name

  Phone

  Fax

  e-mail

  	
  S.Jayanthi

  00 91 44 22452846

  00 91 44 22452462

  jayanthi@shasun.com

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  NON-MEDICAL
  CUSTOMER COMPLAINTS

  	
   

  	
  Name

  Phone

  	
  Medical
  Affairs

  (908) 580-1200

  	
   

  	
  Name

  Phone

  Fax

  e-mail

  	
  B.Saravanakumar

  

  

  saravanan@shasun.com

  

 

1

 

IV                                   MANUFACTURING
COMPLIANCE

 

The Product
will be manufactured by Shasun pursuant to the Supply Agreement at the Shasun facility(s)
located at A-1/B, Sipcot Industrial Complex, Kudikadu Village, Cuddalore 607
005 (FDA facility registration # 3003585876). All manufacturing activities
shall conform to the requirements of ICH Guidance for Industry Q7A Good
Manufacturing Practice Guidance for Active Pharmaceutical Ingredients, and FDA
Guide for Manufacturing, Processing and Holding APIs.

 

1.                                      Premises

 

1.1                                 The
manufacturing facility(s) shall comply with all aspects of ICH Q7A section 4
Buildings and Facilities, as well as all additional requirements detailed in
the DMF and Supply Agreement.

 

2.                                      Equipment

 

2.1                                 Equipment
used to manufacture the Product shall comply with Q7A section 5 Process
Equipment, as well as all additional requirements detailed in DMF # 13192.

 

2.2                                 Shasun
shall maintain written records for usage, cleaning, maintenance, and
calibration of all equipment used in the processing of the Products to ensure
that cleaning and maintenance records are readily identifiable with equipment
usage in the event of a drug product problem that may be investigated. Shasun
shall maintain approved written procedures including, but not limited to,
specifications for cleaning, assignment of responsibility for cleaning and
maintaining equipment.

 

2.3                                 Installation
qualification (1Q)/ operational qualification (OQ)/ performance qualification
(PQ) shall be performed on all equipment used in analysis of the Products, and
the same equipment shall be placed on a calibration and/or preventive
maintenance schedule, as appropriate.

 

2.4                                 Shasun
shall only use the major equipment detailed in the DMF for the processing and
manufacture of the Product. Product manufactured in equipment other than that
stipulated in the filed Master Batch production records shall not be accepted.

 

3.                                      Personnel

 

3.1                                 Personnel
used to manufacture the Product shall comply with Q7A section 3 Personnel, as
well as any additional requirements defined by procedure. These
responsibilities shall be defined in written procedures.

 

3.2                                 The
training of personnel used to process the Product shall be appropriately
documented and available for review. Training shall be conducted on a
continuing basis by qualified individuals.

 

2

 

3.3                                 There
shall be an adequate number of qualified personnel to perform and supervise the
processing and manufacture of the Product.

 

4.                                      Materials

 

4.1                                 Control
of materials used to process the Product shall comply with Q7A section 7
Materials Management, as well as all additional requirements detailed in DMF,
or required by written procedures.

 

4.2                                 Shasun
shall use production materials from approved suppliers as detailed in the DMF,
and required by ICH Q7A section 16 Contract Manufacturers.

 

4.3                                 Shasun
shall sample all production materials according to approved procedures, and
shall test and release those materials according to approved analytical
methodology and specifications as filled in the DMF.

 

4.4                                 Shasun
shall store all packaging materials, production materials, and finished API in
a suitable environment so as not to impact the materials’ quality. A suitable
retest program shall be used to demonstrate the quality of the stored material
versus approved specifications. Certificates of Analysis shall be generated, as
required for Reliant, for finished API.

 

4.5                                 All
production materials used in the manufacture of the Products shall be tested in
accordance with Shasun standard operating procedures, using approved methods
and specifications.

 

5.                                      Documentation

 

5.1                                 Documentation
used to support the manufacture of the Product shall comply with Q7A section 6
Documentation and Records, as well as all additional requirements detailed in
DMF or required by Shasun.

 

5.2                                 Shasun
shall follow written documentation in the form of a Maste Batch Record for all
processes used in the manufacture of the Products. These records shall be made
available during any compliance audit of the site.

 

5.3                                 Shasun
shall maintain and follow all Standard Operating procedures (SOPs) required to
manufacture, package, analyze, release, and store the Product as detailed in
the DMF, and required by ICH Q7A.

 

5.4                                 Shasun
shall follow a suitable, internal, change control procedure for all
documentation. All changes to batch records, manufacturing specifications, test
methods, or sources of intermediates which have direct impact on the Safety,
Identity, Purity, or Quality of the API must be submitted to Reliant QA for
review and approval prior to implementation.

 

3

 

6.                                      Lot
Numbers and Expiration

 

6.1                                 Shasun
shall assign unique lot numbers finished API to ensure complete product
traceability.

 

6.2                                 The
Product lot retest period will be based on approved procedures and the approved
retest period as filed to the DMF.

 

7.                                      Product
Storage and Shipment

 

7.1                                 Storage
and shipment of the Product shall comply with Q7A section 10 Storage and
Distribution, section 17 Agents, Brokers, Traders, Distributors, Repackers, and
Relabellers, as well as all additional requirements detailed in DMF, or required
by Shasun.

 

7.2                                 Shasun
shall store all finished product in suitable containers, labeled with lot
specific information, as required by the DMF, and as detailed in the Supply
Agreement, and in a controlled environment under appropriate temperature and
humidity conditions.

 

7.3                                 Only
finished Product having an approved Certificate of Analysis may be shipped by
Shasun to a Reliant specified address. Reliant QA is the only agent authorized
to release the finished pharmaceutical product into commercial distribution.
Materials may be shipped under Quarantine from time-to-time as warranted, but
only upon the request of Reliant and with the prior written consent from the
Quality Departments from Reliant and Shasun. It is anticipated that Quarantine
shipments will have a low frequency of occurrence.

 

7.4                                 Shasun
shall segregate product by lot number prior to shipment.

 

V                                       QUALITY CONTROL

 

All testing
shall be done in accordance with the filed DMF, and all additional requirements
detailed in ICH Guidance for Industry Q7A Good Manufacturing Practice Guidance
for Active Pharmaceutical Ingredients, and FDA Guide for Manufacturing,
Processing and Holding APIs

 

1.                                      Premises

 

1.1                                 The
quality control laboratory shall comply with all aspects of ICH Q7A section 11
Laboratory Control as well as all additional requirements detailed in the DMF.

 

2.                                      Equipment

 

2.1                                 Installation
qualification (IQ)/operational qualification (OQ)/performance qualification
(PQ) shall be performed on all equipment used

 

4

 

in analysis of the Product, and the same equipment shall be placed on a
calibration and/or preventive maintenance schedule, as appropriate.

 

2.2                                 Shasun
shall maintain written records for equipment usage, maintenance and
calibration.

 

3.                                      Vendor
Approval

 

3.1                                 Shasun
shall suitably qualify all vendors from which materials are sourced for use in
the finished drug product. This includes, but is not limited to excipients,
API, container closure systems, printed commodities, etc. For those materials
provided to Shasun by Reliant (i.e. labels, cartons, and package inserts),
Reliant shall have the responsibility for qualification, if these vendors are
not already approved Shasun vendors.

 

4.                                      Personnel

 

4.1                                 Personnel
used to test and release the Product shall comply with Q7A section 3 Personnel,
as well as any additional requirements defined by procedure. These
responsibilities shall be defined in written procedures, and shall demonstrate
that individuals understand the methods and techniques they utilize. Training
shall be documented and is open for review. Training shall be conducted on a
continuing basis by qualified individuals.

 

5.                                      Out-of-Specification
(OOS) Investigations

 

5.1                                 Shasun
is responsible for following its SOP to investigate any test results that fail
to meet specifications.

 

6.                                      Reference
Standards

 

6.1                                 Shasun
shall use appropriately qualified reference standards that comply with current
ICH guidelines to release the Product.

 

7.                                      Product
Release

 

7.1                                 Reliant
shall only accept finished APIt that complies with the DMF and with the Supply
Agreement.

 

8.                                      Stability

 

8.1                                 Materials
shall be placed on stability per an approved protocol and shall be conducted in
accordance with Shasun Standard Operating Procedures.

 

5

 

VI                                   QUALITY
ASSURANCE

 

Shasun shall
maintain a quality department that complies with all aspects of ICH Q7A section
2 Quality Management to assure that the Product was manufactured, tested,
released, and stored in accordance with all requirements detailed in the DMF, and
as required by ICH and FDA.

 

1.                                      Documentation

 

1.1                                 Documentation
used to support the processing, testing and release of the Product shall comply
with ICH Q7A section 6 Documentation and Records, as well as all additional
requirements detailed in DMF or required by Shasun.

 

1.2                                 Shasun
shall provide a Certificate of Analysis indicating all regulatory test results
and their specifications, and a Certificate of Compliance indicating the drug
product has been manufactured, tested, and stored according to cGMP’s and all
requirements as detailed in the DMF. These two documents can be combined into
one, per current Shasun format.

 

2.                                      Samples

 

2.1                                 Shasun’s
Quality Unit shall assure that all samples are taken in accordance with ICH Q7A
section 8 Production and In-Process Controls, approved SOP’s and as detailed in
the DMF.

 

2.2                                 Shasun
shall maintain finished Product Reserve samples for a period of not less than
one year past the expiration date of the batch, or for 3 years after distribution
of the batch, whichever is longer. At least twice as much material shall be
retained as is needed to conduct all specification release testing.

 

2.3                                 Reserve
samples shall be retained and stored under conditions consistent with product
labeling. The reserve sample shall be stored in the same immediate container-closure
system in which the Product is marketed or in one that has essentially the same
characteristics.

 

3.                                      Change
Control

 

3.1                                 Shasun
shall follow a suitable change control process as defined by ICH Q7A section 13
Change Control. All Changes that impact the specifications, yield, quality, etc
of the API must be submitted to Reliant QA for review and approval prior to
implementation as such changes may require a Prior Approval Supplement to the
affected NDA.

 

3.2                                 Reliant
shall have seven business days from the date of submission of a change request
from Shasun in which to review the documentation and provide Shasun with
comment or approval. Any supporting documentation

 

6

 

requested by Reliant to determine acceptability of the change request
shall be provided by Shasun.

 

3.3                                 Shasun
must provide Reliant with acceptable supporting data and documentation to
support any filing to the approved NDA. Such documentation shall meet all FDA
and ICH criteria.

 

3.4                                 The
change may be implemented upon approval of the change to the NDA by FDA.

 

4.                                      Product
Complaints or Adverse Events

 

4.1                                 API
individuals reporting a finished pharmaceutical product related complaint
should be immediately directed to contact Reliant’s Customer Complaints Group
at 908-580-1200.

 

4.1.1                        Reliant
shall maintain a system to receive, log, evaluate, categorize, communicate, and
follow-up each complaint received.

 

4.2                                 Shasun
shall maintain a system as required by ICH Q7A section 15 Complaints and
Recalls, to handle product complaints.

 

4.2.1                        Shasun
shall notify Reliant QA of any complaint received by Shasun that may have
impact on the quality of API distributed to Reliant within 2 business days of
receipt of such complaint.

 

4.2.2                        Shasun
shall provide a final investigation report to Reliant QA for complaints on lots,
or complaints that may affect lots received by Reliant.

 

4.3                                 API
individuals reporting an Adverse Event (AE) should be immediately directed to
contact Reliant’s Medical Affairs Department at 908-580-1200.

 

4.4                                 Reliant
shall be the only authorized group to provide product related responses to the
public.

 

4.5                                 Should
Reliant discover a product related problem, Reliant Quality Department shall
provide a written complaint notification to Shasun within 1 business day of the
occurrence.

 

5.                                      Product
Quality Review

 

5.1                                 Shasun
shall perform an annual product review as required by ICH Q7A section 2 part E
Product Quality Review. A copy of the summary of the product quality review
shall be provided to Reliant QA.

 

7

 

6.                                      Product
Recalls

 

6.1                                 Shasun
shall notify Reliant within two business days of an event that may necessitate
a product recall as define in ICH Q7A section 17 part G Handling Complaints and
Recalls. It shall be the sole responsibility of Reliant to issue a FDA Field Alert
Notification pertaining to a finished pharmaceutical product quality issue
discovered by Shasun or Reliant. An alert shall only be issued with substantive
evidence of a quality issue. Shasun shall provide Reliant with a written report
detailing the quality issue for which a product recall action was initiated.

 

6.2                                 It
shall be the sole responsibility of Reliant to issue a product recall, and
discuss with FDA the extent or type of action that should occur. Decisions to
initiate a product recall shall be based on product medical reviews and the
investigation report used to support the FDA Field Alert.

 

7.                                      Audits
by Reliant Pharmaceuticals

 

7.1                                 Reliant
Pharmaceuticals shall have the right to perform audits of departments
responsible in the manufacture of the Products at least annually. Shasun shall
provide Reliant Quality, or representative, access to all facilities and records
pertaining to the manufacture of the product.

 

7.2                                 Reliant
Quality shall provide 20 business days notification for a routine audit, and
five business days’ notification for a ‘for cause’ audit pertaining to product
quality or safety.

 

7.3                                 Reliant
Quality, or representative, shall provide an exit meeting to Shasun management
to detail significant observations. A written report of observations shall be
issued to Shasun QA.

 

7.4                                 Shasun
shall provide a written response to the audit observations within 20 business
days. The response shall include details of the corrective actions to the
observations, and the expected completion date of the action. Reliant Quality
shall follow-up on the progress of the corrective actions based on the expected
completion dates provided.

 

VII                               REGULATORY

 

All final,
Regulatory assessments pertaining to the manufacture, release, and distribution
of the finished pharmaceutical products shall be the responsibility of Reliant’s
Regulatory Affairs group.

 

1.                                      Inspections
by Regulatory Agencies

 

1.1                                 Shasun
shall inform Reliant Pharmaceuticals of any Regulatory Agency performing an
inspection relating to the Product(s), or a facilities inspection affecting the
Product(s) within two business day of notification.

 

8

 

1.2                                 All
Product(s) specific regulatory correspondence, or facilities correspondence
affecting the manufacturing of the Product(s) shall be conveyed to Reliant
Quality Department within 2 business days of receipt. For any response specific
to a Reliant Product, Shasun shall provide written responses to observations
for Reliant review prior to commitment to any regulatory authority.

 

1.3                                 Shasun
shall provide copies of all regulatory agency inspection documentation (i.e.
483’s, EIR’s, etc.) or any other regulatory correspondence pertaining to the
Product or facility to Reliant Quality Department within two business days of
receipt. A redacted copy may be provided to protect other customer’s products.

 

2.                                      Annual
Reports

 

2.1                                 It
shall be the sole responsibility of Reliant Pharmaceuticals to maintain all
regulatory communication and updates (Supplements, CBE, Annual Reports, etc.)
pertaining to the finished pharmaceutical Product as outlined in ICH and FDA
regulatory guidance documents. All necessary supporting CMC documents be
provided to Reliant Regulatory by Shasun

 

3.                                      Drug
Listing

 

3.1                                 It
shall be the responsibility of Reliant Regulatory to submit FDA Form #2657
every June and December updating the finished pharmaceutical Drug Product Listing.
When no changes have occurred since the previously submitted list, no response
is required.

 

VIII                           VALIDATION

 

Shasun shall
assure that all systems used to manufacture, test, release, and distribute the
Product shall comply with ICH Q7A section 12 Validation, as well as additional
in-house requirements. All systems will have been appropriately transferred,
qualified, and/or validated prior to using that system in the processing of the
Product. All such records are open for review during an audit.

 

1.                                      Process

 

1.1                                 Shasun
shall be responsible for performing and documenting process validation to
comply with cGMP’s and to ensure consistency of quality Product.

 

2.                                      Equipment
Cleaning Validation

 

2.1                                 Shasun
is responsible for reviewing toxicity and safety information for all products
they manufacture to set appropriate cleaning limits to ensure there are no
cross contamination issues between products. Shasun shall

 

9

 

demonstrate, through approved protocol and final report, that cleaning
validation has been performed for the Product(s).

 

3.                                      Analytical
Test Methods

 

3.1                                 Shasun
shall be responsible for demonstrating the validity of all methodology used for
in-process control, and release of process materials, intermediates, and API.
This validation shall be established, through approved protocol and final
report, based on the current ICH and FDA validation guidance documents. Method
validation shall be performed consistent with Shasun-approved procedures.

 

4.                                      Computer

 

4.1                                 Shasun
is responsible for compliance as it pertains to systems validation, electronic
records, electronic records retention, and electronic signatures for those
systems used in the control of the manufacturing processes, analytical testing,
receipt, release and distribution of materials, components, and API as
prescribed by 21 CFR part 11, and any other current, approved FDA Guidance
requirements.

 

10

 

REVISION HISTORY

 

	
  Revision Date

  	
   

  	
  Revision Description

  
	
  August 2004

  	
   

  	
  New Document

  

 

APPROVALS

 

	
  Reliant Pharmaceuticals, Inc. 

  	
   

  	
  Shasun Chemicals and Drug, Ltd.

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Signature

  	
  Date

  	
  Signature

  	
  Date

  
	
   

  	
   

  	
   

  	
   

  
	
  Godfrey Baker

  Associate Director, QA/QC

  	
   

  	
  V.Rajasekaran

  Head – Quality

  	
   

  
						

 

11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00131-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00131-of-00352.parquet"}]]